



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 1 OF 16

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001

GROUP: 1644

## U.S. PATENT DOCUMENTS

| EXAM.<br>INIT. |     | DOCUMENT<br>NUMBER | DATE     | NAME             | CLASS | SUB<br>CLASS | FILING DATE IF<br>APPROPRIATE |
|----------------|-----|--------------------|----------|------------------|-------|--------------|-------------------------------|
|                | A1  | 07/348,237         | 5/5/89   | Rosenblum et al. |       |              |                               |
|                | A2  | 4,196,265          | 4/1/80   | Koprowski et al. |       |              |                               |
|                | A3  | 4,469,797          | 9/4/84   | Albarella        |       |              |                               |
|                | A4  | 4,676,980          | 6/30/87  | Segal et al.     |       |              |                               |
|                | A5  | 4,816,567          | 3/28/89  | Cabilly et al.   |       |              |                               |
|                | A6  | 4,946,778          | 8/7/90   | Ladner et al.    |       |              |                               |
|                | A7  | 5,019,368          | 5/28/91  | Epstein et al.   |       |              |                               |
|                | A8  | 5,073,627          | 12/17/91 | Curtis et al.    |       |              |                               |
|                | A9  | 5,114,711          | 5/19/92  | Bell et al.      |       |              |                               |
|                | A10 | 5,116,964          | 5/26/92  | Capon et al.     |       |              |                               |
|                | A11 | 5,199,942          | 4/6/93   | Gillis           |       |              |                               |
|                | A12 | 5,225,538          | 7/6/93   | Capon et al.     |       |              |                               |
|                | A13 | 5,225,539          | 7/6/93   | Winter           |       |              |                               |
|                | A14 | 5,258,498          | 11/2/93  | Huston et al.    |       |              |                               |
|                | A15 | 5,314,995          | 5/24/94  | Fell, Jr. et al. |       |              |                               |
|                | A16 | 5,349,053          | 9/20/94  | Landolfi         |       |              |                               |
|                | A17 | 5,359,035          | 10/25/94 | Habermann        |       |              |                               |
|                | A18 | 5,514,582          | 5/7/96   | Capon et al.     |       |              |                               |
|                | A19 | 5,538,866          | 7/23/96  | Israeli et al.   |       |              |                               |
|                | A20 | 5,541,087          | 7/30/96  | Lo et al.        |       |              |                               |
|                | A21 | 5,543,297          | 8/6/96   | Cromlish, et al. |       |              |                               |
|                | A22 | 5,552,524          | 09/03/96 | Basinski et al.  |       |              |                               |
|                | A23 | 5,585,089          | 12/17/96 | Queen et al.     |       |              |                               |
|                | A24 | 5,609,846          | 3/11/97  | Goldenberg       |       |              |                               |
|                | A25 | 5,624,821          | 4/29/97  | Winter et al.    |       |              |                               |

RECEIVED

NOV 10 2003

TECH CENTER 1600/2900

EXAMINER David A. Saunders

DATE CONSIDERED

3/1/04

des  
7/5/05

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

|            |     |           |          |                     |   |   |  |
|------------|-----|-----------|----------|---------------------|---|---|--|
| <i>all</i> | A26 | 5,639,725 | 6/17/97  | O'Reilly et al.     | — | ✓ |  |
|            | A27 | 5,645,835 | 7/8/97   | Fell, Jr. et al.    | — | ✓ |  |
|            | A28 | 5,650,492 | 7/22/97  | Gately et al.       | — | ✓ |  |
|            | A29 | 5,667,776 | 9/16/97  | Zimmerman et al.    | — | ✓ |  |
|            | A30 | 5,679,543 | 10/21/97 | Lawlis              | — | ✓ |  |
|            | A31 | 5,691,309 | 11/25/97 | Basinski et al.     | ✓ | — |  |
|            | A32 | 5,709,859 | 1/20/98  | Aruffo et al.       | ✓ | — |  |
|            | A33 | 5,719,266 | 02/17/98 | DiMarchi et al.     | — | — |  |
|            | A34 | 5,726,044 | 3/10/98  | Lo et al.           | — | — |  |
|            | A35 | 5,728,552 | 3/17/98  | Fujisawa et al.     | — | — |  |
|            | A36 | 5,733,876 | 3/31/98  | O'Reilly et al.     | — | — |  |
|            | A37 | 5,756,461 | 05/26/98 | Stephens            | — | — |  |
|            | A38 | 5,759,551 | 6/2/98   | Ladd et al.         | — | — |  |
|            | A39 | 5,770,195 | 6/23/98  | Hudziak et al.      | — | ✓ |  |
|            | A40 | 5,800,810 | 9/1/98   | Doyle et al.        | — | — |  |
|            | A41 | 5,807,715 | 9/15/98  | Morrison et al.     | — | — |  |
|            | A42 | 5,827,516 | 10/27/98 | Urban et al.        | — | — |  |
|            | A43 | 5,837,682 | 11/17/98 | Folkman et al.      | — | — |  |
|            | A44 | 5,843,423 | 12/1/98  | Lyman et al.        | — | — |  |
|            | A45 | 5,854,205 | 12/29/98 | O'Reilly et al.     | ✓ | — |  |
|            | A46 | 5,856,298 | 1/5/99   | Strickland          | ✓ | — |  |
|            | A47 | 5,858,347 | 1/12/99  | Bauer et al.        | — | — |  |
|            | A48 | 5,885,795 | 3/23/99  | O'Reilly et al.     | — | — |  |
|            | A49 | 5,886,178 | 3/23/99  | Allen et al.        | — | — |  |
|            | A50 | 5,888,772 | 3/30/99  | Okasinski et al.    | — | — |  |
|            | A51 | 5,922,685 | 7/13/99  | Rakhmilevich et al. | — | — |  |
|            | A52 | 5,994,126 | 11/30/99 | Steinman et al.     | ✓ | — |  |
| ✓          | A53 | 6,080,409 | 6/27/00  | Laus et al.         | — | — |  |

**RECEIVED**

NOV 1 0-2803

TECH CENTER 1600/2200

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*3/1/04*



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 3 OF 16

|  |   |
|--|---|
| FORM PTO - 1449                                  | ATTORNEY DOCKET NO.: LEX-011 (4006/23)          |
| SUPPLEMENTAL INFORMATION<br>DISCLOSURE STATEMENT | APPLICANT(S): Gillies et al.                    |
|  | SERIAL NO.: 09/780,668      CONF.: 8264         |
|  | FILING DATE: February 09, 2001      GROUP: 1644 |

|            |     |           |         |                   |                                     |                          |  |
|------------|-----|-----------|---------|-------------------|-------------------------------------|--------------------------|--|
| <i>gnt</i> | A54 | 6,086,875 | 7/11/00 | Blumberg et al.   | <input checked="" type="checkbox"/> | <input type="checkbox"/> |  |
|            | A55 | 6,169,070 | 1/2/01  | Chen et al.       | <input checked="" type="checkbox"/> | <input type="checkbox"/> |  |
|            | A56 | 6,171,588 | 1/9/01  | Carron et al.     | <input type="checkbox"/>            | <input type="checkbox"/> |  |
|            | A57 | 6,277,375 | 8/21/01 | Ward              | <input type="checkbox"/>            | <input type="checkbox"/> |  |
|            | A58 | 6,348,192 | 2/19/02 | Chan et al.       | <input type="checkbox"/>            | <input type="checkbox"/> |  |
|            | A59 | 6,406,689 | 6/18/02 | Falkenberg et al. | <input type="checkbox"/>            | <input type="checkbox"/> |  |

## FOREIGN PATENT DOCUMENTS

| EXAM.<br>INIT. |     | DOCUMENT<br>NUMBER | DATE     | COUNTRY<br>CODE | CLASS                    | SUB<br>CLASS             | FILING<br>DATE | ABSTRACT<br>ONLY | ENGLISH<br>LANG<br>(Y/N) |
|----------------|-----|--------------------|----------|-----------------|--------------------------|--------------------------|----------------|------------------|--------------------------|
| <i>gnt</i>     | B1  | 0 158 198 A1       | 10/16/85 | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B2  | 0 211 769 A2       | 2/25/87  | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B3  | 0 256 714 A2       | 2/24/88  | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B4  | 0 294 703 A2       | 12/14/88 | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B5  | 0 308 936 B1       | 3/29/89  | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B6  | 0 314 317 B1       | 5/3/89   | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B7  | 0 318 554 B1       | 6/7/89   | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B8  | 0 319 012 A2       | 6/7/89   | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B9  | 0 326 120 B1       | 8/2/89   | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B10 | 0 350 230 A2       | 1/10/90  | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B11 | 0 375 562 B1       | 6/27/90  | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B12 | 0 396 387 A2       | 11/7/90  | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B13 | 0 439 095 A2       | 7/31/91  | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B14 | 0 511 747 A1       | 11/4/92  | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B15 | 0 601 043 B1       | 6/15/94  | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B16 | 0 640 619 A1       | 3/1/95   | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B17 | 0 668 353 A1       | 8/23/95  | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
|                | B18 | 0 706 799 A2       | 4/17/96  | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |
| <i>✓</i>       | B19 | 0 790 309 A1       | 8/20/97  | EP              | <input type="checkbox"/> | <input type="checkbox"/> |                |                  | Y                        |

RECEIVED  
NOV 1 4 2003  
TECH CENTER 1600/2900

EXAMINER

*Daniel A. Saunders*

DATE CONSIDERED

*3/1/04*

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

|            |                |                        |                    |               |   |   |  |              |
|------------|----------------|------------------------|--------------------|---------------|---|---|--|--------------|
| <i>sub</i> | B20            | 21725/88               | 3/23/89            | AU            | — | — |  | Y            |
|            | <del>B21</del> | <del>931001153</del>   | <del>7/14/93</del> | <del>CN</del> | — | — |  | <del>N</del> |
| <i>sub</i> | B22            | 931001153              | 7/14/93            | CN            | — | — | Y                                      | Y            |
|            | <del>B23</del> | <del>37 12985 A1</del> | <del>11/9/88</del> | <del>DE</del> | — | — |  | <del>N</del> |
| <i>sub</i> | B24            | 37 12985               | 11/2/88            | DE            | — | — | Y                                      | Y            |
| <i>sub</i> | B25            | 2 292 382 A            | 2/21/96            | GB            | — | — |  | Y            |
|            | <del>B26</del> | <del>63-267278</del>   | <del>11/4/88</del> | <del>JP</del> | — | — |  | <del>N</del> |
| <i>sub</i> | B27            | 63-267278              | 11/4/88            | JP            | — | — | Y                                      | Y            |
|            | <del>B28</del> | <del>63-267296</del>   | <del>11/4/88</del> | <del>JP</del> | — | — |  | <del>N</del> |
| <i>sub</i> | B29            | 63-267296              | 11/4/88            | JP            | — | — | Y                                      | Y            |
|            | B30            | 0 237 019 A2           | 9/16/87            | EP            | — | — | English counterpart<br>of JP 63-267296 | Y            |
|            | B31            | WO 86/01533            | 3/13/86            | PCT           | — | — |  | Y            |
|            | B32            | WO 88/00052            | 1/14/88            | PCT           | — | — |  | Y            |
|            | B33            | WO 88/09344            | 12/1/88            | PCT           | — | — |  | Y            |
|            | B34            | WO 89/02922            | 4/6/89             | PCT           | — | — |  | Y            |
|            | B35            | WO 89/09620            | 10/19/89           | PCT           | — | — | Abstract in English                    | N            |
|            | B36            | WO 90/03801            | 4/19/90            | PCT           | — | — |  | Y            |
|            | B37            | WO 91/00360            | 1/10/91            | PCT           | — | — |  | Y            |
|            | B38            | WO 91/04329            | 04/04/91           | PCT           | — | — |  | Y            |
|            | B39            | WO 91/08298            | 6/13/91            | PCT           | — | — |  | Y            |
|            | B40            | WO 91/13166            | 9/5/91             | PCT           | — | — |  | Y            |
|            | B41            | WO 91/14438            | 10/3/91            | PCT           | — | — |  | Y            |
|            | B42            | WO 92/02240            | 2/20/92            | PCT           | — | — |  | Y            |
|            | B43            | WO 92/08495            | 5/29/92            | PCT           | — | — |  | Y            |
|            | B44            | WO 92/08801            | 5/29/92            | PCT           | — | — |  | Y            |
|            | B45            | WO 92/16562            | 10/1/92            | PCT           | — | — |  | Y            |
|            | B46            | WO 93/03157            | 2/18/93            | PCT           | — | — |  | Y            |
| <i>✓</i>   | B47            | WO 93/10229            | 5/27/93            | PCT           | — | — |  | Y            |

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*3/1/04*

RECEIVED  
NOV 1 9 2003  
TECH CENTER 1600/2900



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 5 OF 16

| FORM PTO - 1449<br>SUPPLEMENTAL INFORMATION<br>DISCLOSURE STATEMENT |     |             |          |     | ATTORNEY DOCKET NO.: LEX-011 (4006/23)<br>APPLICANT(S): Gillies et al.<br>SERIAL NO.: 09/780,668 CONF.: 8264<br>FILING DATE: February 09, 2001 GROUP: 1644 |   |  |  |   |
|---|-----|-------------|----------|-----|--|---|--|--|---|
| <i>Del</i>  | B48 | WO 94/24160 | 10/27/94 | PCT | /  | / |  |  | Y |
|   | B49 | WO 94/25055 | 11/10/94 | PCT | /  | / |  |  | Y |
|   | B50 | WO 95/05468 | 2/23/95  | PCT | /  | / |  |  | Y |
|   | B51 | WO 95/21258 | 8/10/95  | PCT | /  | / |  |  | Y |
|   | B52 | WO 95/28427 | 10/26/95 | PCT | /  | / |  |  | Y |
|   | B53 | WO 95/31483 | 11/23/95 | PCT | /  | / |  |  | Y |
|   | B54 | WO 96/04388 | 02/15/96 | PCT | /  | / |  |  | Y |
|   | B55 | WO 96/05309 | 2/22/96  | PCT | /  | / |  |  | Y |
|   | B56 | WO 96/08570 | 3/21/96  | PCT | /  | / |  |  | Y |
|   | B57 | WO 96/31526 | 10/10/96 | PCT | /  | / |  |  | Y |
|   | B58 | WO 97/00317 | 1/3/97   | PCT | /  | / |  |  | Y |
|   | B59 | WO 97/15666 | 5/1/97   | PCT | /  | / |  |  | Y |
|   | B60 | WO 97/20062 | 6/5/97   | PCT | /  | / |  |  | Y |
|   | B61 | WO 97/24137 | 7/10/97  | PCT | /  | / |  |  | Y |
|   | B62 | WO 97/24440 | 7/10/97  | PCT | /  | / |  |  | Y |
|   | B63 | WO 97/26335 | 7/24/97  | PCT | /  | / |  |  | Y |
|   | B64 | WO 97/30089 | 8/21/97  | PCT | /  | / |  |  | Y |
|   | B65 | WO 97/33617 | 9/18/97  | PCT | /  | / |  |  | Y |
|   | B66 | WO 97/33619 | 9/18/97  | PCT | /  | / |  |  | Y |
|   | B67 | WO 97/34631 | 9/25/97  | PCT | /  | / |  |  | Y |
|   | B68 | WO 97/43316 | 11/20/97 | PCT | /  | / |  |  | Y |
|   | B69 | WO 98/00127 | 1/8/98   | PCT | /  | / |  |  | Y |
|   | B70 | WO 98/06752 | 2/19/98  | PCT | /  | / |  |  | Y |
|   | B71 | WO 98/28427 | 7/2/98   | PCT | /  | / |  |  | Y |
|   | B72 | WO 98/30706 | 7/16/98  | PCT | /  | / |  |  | Y |
|   | B73 | WO 98/46257 | 10/22/98 | PCT | /  | / |  |  | Y |
|   | B74 | WO 98/59244 | 12/30/98 | PCT | /  | / |  |  | Y |
| <i>✓</i>  | B75 | WO 99/02709 | 01/21/99 | PCT | /  | / |  |  | Y |

RECEIVED  
NOV 10 2003  
TECH CENTER 1600/2900

|                                  |                               |
|----------------------------------|-------------------------------|
| EXAMINER <i>David A. Summers</i> | DATE CONSIDERED <i>3/1/04</i> |
|----------------------------------|-------------------------------|



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 6 OF 16

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

|            |     |                    |          |     |                                     |                                     |  |  |   |
|------------|-----|--------------------|----------|-----|-------------------------------------|-------------------------------------|--|--|---|
| <i>gus</i> | B76 | WO 99/03887        | 01/28/99 | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B77 | WO 99/29732        | 6/17/99  | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B78 | WO 99/52562        | 10/21/99 | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B79 | WO 99/53958        | 10/28/99 | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B80 | WO 99/60128        | 11/25/99 | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B81 | WO 99/62944        | 12/09/99 | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B82 | WO 99/66054        | 12/23/99 | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B83 | WO 00/11033        | 3/2/00   | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B84 | WO 00/34317        | 06/15/00 | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B85 | WO 00/40615        | 7/13/00  | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B86 | WO 00/68376        | 11/16/00 | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B87 | WO 00/69913        | 11/23/00 | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B88 | WO 00/78334<br>A1  | 12/28/00 | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B89 | WO 01/07081<br>A1  | 2/1/01   | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B90 | WO 01/10912-<br>A1 | 2/15/01  | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |
|            | B91 | WO<br>03/015697 A2 | 2/27/03  | PCT | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |  |  | Y |

EXAM.  
INIT.

OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)


|            |    |  |
|------------|----|--|
| <i>gus</i> | C1 | Abaza et al., (1992), "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization," <u>Journal of Protein Chemistry</u> , 11:5:433-444. |
|            | C2 | Abstract XP-002116766, (1996), "Prostaglandins, their inhibitors and cancer," <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> , 54:2:83-94.  |
|            | C3 | Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237.  |
|            | C4 | Arenberg et al. (1996), "Interferon- $\gamma$ -inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> , 184:981-992.            |

EXAMINER

*David A. Shumaker*

DATE CONSIDERED

*3/1/04*RECEIVED  
NOV 10 2003  
TECH CENTER 1600/2900



FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

|            |     |  |
|------------|-----|--|
| <i>Def</i> | C5  | Bacha et al., (1988), "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein," <u>J. Experimental Medicine</u> , 167:612-622  |
|            | C6  | Bachelot et al., (March 1998), "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo," <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , 39:271, Abstract #1856.                       |
|            | C7  | Barnett et al., (1994), "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," <u>Biochimica et Biophysica Acta</u> , 1209:130-139.  |
|            | C8  | Baselga, et al., (1998), "Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor activity of Paclitaxel and Doxorubicin against HER3/ <i>neu</i> Overexpressing Human Breast Cancer Xenografts," <u>Cancer Research</u> , 58:2825-2831.  |
|            | C9  | Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," <u>Mol. Immunol.</u> , 30:379-386.  |
|            | C10 | Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci.</u> , 93:7826-7831.  |
|            | C11 | Becker et al., (1996), "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," <u>Proc. Natl. Acad. Sci. USA</u> , 93:2702-2707.  |
|            | C12 | Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," <u>Ann. Rev. Biochem.</u> , 57:505-518.  |
|            | C13 | Bissery et al., (1997), "The Taxoids," in <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Tech. ed., 175-193.   |
|            | C14 | Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins," <u>Cancer Research</u> , 45:1214-1221.  |
|            | C15 | Boehm et al., (1997), "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," <u>Nature</u> , 390:404-407.   |
|            | C16 | Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," <u>Biochemical and Biophysical Research Communications</u> , 252:190-194.   |
|            | C17 | Boissel et al., (1993), "Erythropoietin Structure-Function Relationships," <u>The Journal of Biological Chemistry</u> , 268:15983-15993.   |
|            | C18 | Brooks et al., (1994), "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <u>Cell</u> , 79:1157-1164.  |
|            | C19 | Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307:2:411-415.   |
| <i>X</i>   | C20 | Burgess et al., (1990), "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>Journal of Cell Biology</u> , 111:2129-2138. |

RECEIVED  
NOV 10 2003  
TECH CENTER 1600/2300

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*2/26/04*



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 8 OF 16

|   |     |   |
|---|-----|---|
| FROM PTO - 1449                               |     | ATTORNEY DOCKET NO.: LEX-011 (4006/23)  |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT |     | APPLICANT(S): Gillies et al.  |
|   |     | SERIAL NO.: 09/780,668      CONF.: 8264   |
|   |     | FILING DATE: February 09, 2001      GROUP: 1644   |
| Day   | C21 | Canfield et al., (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," <u>Journal of Experimental Medicine</u> , 173:6:1483-1491.                 |
|   | C22 | Cao et al., (1996), "Kringle Domains of Human Angiostatin," <u>The Journal of Biological Chemistry</u> , 271:46:29461-29467.  |
|   | C23 | Cao et al., (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," <u>The Journal of Biological Chemistry</u> , 272:36:22924-22928.  |
|   | C24 | Capon et al., (1989), "Designing CD4 immunoadhesins for AIDS therapy," <u>Nature</u> , 337:525-531.   |
|   | C25 | Caton et al., (1986), "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin," <u>The EMBO Journal</u> , 5:7:1577-1587.   |
|   | C26 | Chan et al., (1991), "Induction of Interferon $\gamma$ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," <u>J. Exp. Med.</u> , pp. 869-879.   |
|   | C27 | Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," <u>Seminars in Surgical Oncology</u> , 5:385-390.  |
|   | C28 | Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271:23:13349-13355.  |
|   | C29 | Chaudhary et al., (1988), "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," <u>Nature</u> , 335:370-372.  |
|   | C30 | Chaudhary et al., (1989), "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," <u>Nature</u> , 339:394-397.   |
|   | C31 | Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," <u>Journal of Immunology</u> , 159:1:351-358. |
|   | C32 | Cheon et al., (1994), "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," <u>Proc. Natl. Acad. Sci. USA</u> , 91: 989-993.   |
|   | C33 | Chuang et al., (1993), "Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes," <u>Gynecol. Oncol.</u> , 49:291-298.  |
|   | C34 | Cohen, S. L. et al., (1996), "Human leptin characterization," <u>Nature</u> , 382:589.  |
|   | C35 | Cole et al., (1997), "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," <u>Journal of Immunology</u> , 159:3613-3621.  |
|   | C36 | Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci.</u> , 85:7709-7713.   |
| ✓   | C37 | Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," <u>Cancer Research</u> , 56:2531-2534.   |

RECEIVED  
NOV 20 2003  
TECH CENTER 1600/2900

EXAMINER

David A. Saunders

DATE CONSIDERED

2/26/04





EXPRESS MAIL LABEL NO. EV289510878US

SHEET 9 OF 16

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

|           |     |   |
|-----------|-----|---|
| <i>as</i> | C38 | D'Amato et al., (1994), "Thalidomide is an inhibitor of angiogenesis," <u>Proc. Natl. Acad. Sci. USA</u> , 91:4082-4085.  |
|           | C39 | D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," <u>J. Exp. Med.</u> , 176:1387-1398.  |
|           | C40 | Ding et al., (1988), "Zinc-Dependent Dimers Observed in Crystals of Human Endostatin," <u>Proceedings of the National Academy of Sciences of USA</u> , 95:10443-10448.  |
|           | C41 | Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," <u>J. Cell. Biochem. Supp.</u> , 161:156-166.  |
|           | C42 | Eisenthal, (1990), "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," <u>Cancer Immunol. Immunotherap.</u> 31:342-348. |
|           | C43 | Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," <u>The J. of Immunology</u> , 146:7:2446-2452.                   |
|           | C44 | Fell et al., (1992), "Chimeric L6 antitumor antibody," <u>The J. of Biol. Chem.</u> , 267:15552-15558.  |
|           | C45 | Friedman, J. M. et al., (1998), "Leptin and the regulation of body weight in mammals," <u>Nature</u> , 395:763-770.   |
|           | C46 | Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," <u>Science</u> , 226:1339-1342.   |
|           | C47 | Gately et al., (1998), "The Interleukin-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses," <u>Annu. Rev. Immunol.</u> , 16:495-521.  |
|           | C48 | Gillesen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist," <u>Eur. J. Immunol.</u> , 25:200-206.   |
|           | C49 | Gillies et al., (1989), "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," <u>Bio/Technology</u> , 7:799-804.  |
|           | C50 | Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," <u>J. Immunol. Methods</u> , 125:191-202.  |
|           | C51 | Gillies et al., (1990), "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <u>Hum. Antibod. Hybridomas</u> , 1:1:47-54.   |
|           | C52 | Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," <u>Proc. Natl. Acad. Science</u> , 89:1428-1432.   |
|           | C53 | Gillies et al., (1993), "Biological Activity and In Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , 4:230-235.  |
| <i>↓</i>  | C54 | Gillies et al., (1998), "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases," <u>J. Immunology</u> , 160:2:6195-6203.   |

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*2/26/04*RECEIVED  
NOV 19 2003  
TECH CENTER 1600/2900



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 10 OF 16

|   |     |   |
|---|-----|---|
| FORM PTO - 1449                               |     | ATTORNEY DOCKET NO.: LEX-011 (4006/23)  |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT |     | APPLICANT(S): Gillies et al.  |
|   |     | SERIAL NO.: 09/780,668 CONF.: 8264  |
|   |     | FILING DATE: February 09, 2001 GROUP: 1644  |
| ✓   | C55 | Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <u>Journal of Immunology</u> , 120:6:2027-2032.   |
|   | C56 | Goeddel et al., (1986), "Tumor Necrosis Factors: Gene Structure and Biological Activities," <u>Pharm. Sciences</u> , pp. 597-609.   |
|   | C57 | Gren et al., (1983), "A New Type of Leukocytic Interferon," <u>Dokl. Biochem.</u> , 269:91-95.  |
|   | C58 | Griffon-Etienne et al., (1999), "Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications," <u>Cancer Research</u> , 59:3776-3782.         |
|   | C59 | Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , 73:8:2081-2805.        |
|   | C60 | Guyre et al., (1997), "Increased potency of Fc-receptor-targeted antigens," <u>Cancer Immunol. Immunother.</u> , 45:146-148.  |
|   | C61 | Harris et al., (1993), "Therapeutic Antibodies - the Coming of Age," <u>Tibtech</u> , 11:42-44.   |
|   | C62 | Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds FcYRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," <u>Immunotech.</u> , 1:95-105.                |
|   | C63 | Harvill et al., (1996), "In vivo properties of an IgG3-IL-2 fusion protein: A general strategy for immune potentiation," <u>Journal of Immunology</u> , 157:7:3165-3170.  |
|   | C64 | Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," <u>Vaccine</u> , 11:6:697-636.  |
|   | C65 | He et al., (1998), "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both E and P-Selectin," <u>J. Immunol.</u> , 1029-1035.   |
|   | C66 | Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human FcYRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," <u>J. Clin. Invest.</u> , 97:2:331-338.                                   |
|   | C67 | Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers," <u>J. Immunol.</u> , 158:4381-4388.  |
|   | C68 | Hellstrom et al., (1986), "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," <u>Proc. Natl. Acad. Sci.</u> , 83:18: 7059-7063.  |
|   | C69 | Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," <u>Ann. Rev. Immunol.</u> , 3:31-58.  |
|   | C70 | Herrmann et al., (1989), "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Journal of Clinical Oncology</u> , 7:2:159-167.     |
|   | C71 | Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution," <u>EMBO Journal</u> , 17:6:1656-1664.  |
| ↓   | C72 | Holden et al., (2001), "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents," <u>Proceedings of the American Association for Cancer Research</u> , 42:683, Abstract No. 3675. |
| EXAMINER <i>David A. Saunders</i>             |     | DATE CONSIDERED <i>4/26/04</i>  |

RECEIVED  
NOV 10 2003  
TECH CENTER  
1600/2900



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 11 OF 16

|   |     |  |
|---|-----|--|
| FORM PTO - 1449                               |     | ATTORNEY DOCKET NO.: LEX-011 (4006/23)   |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT |     | APPLICANT(S): Gillies et al.   |
|   |     | SERIAL NO.: 09/780,668      CONF.: 8264  |
|   |     | FILING DATE: February 09, 2001      GROUP: 1644  |
| <input checked="" type="checkbox"/>           | C73 | Holden et al., (2001), "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents," <u>Clinical Cancer Research</u> , 7:2862-2869.   |
| <input type="checkbox"/>                      | C74 | Hoogenboom et al., (1991), "Construction and expression of antibody-tumor necrosis factor fusion proteins," <u>Molecular Immunology</u> , 28:9:1027-1037.  |
| <input type="checkbox"/>                      | C75 | Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," <u>Biochim. and Biophys. Acta</u> , 1096:4:345-354 (Abstract).                           |
| <input type="checkbox"/>                      | C76 | Hornick et al., (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," <u>Clin. Cancer Res.</u> , 5:51-60.  |
| <input type="checkbox"/>                      | C77 | Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004.  |
| <input type="checkbox"/>                      | C78 | Huck et al., (1986), "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cy genes," <u>Nucleic Acids Research</u> , Vol. 14:4:1779-1789.   |
| <input type="checkbox"/>                      | C79 | Huse et al., (1989), "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 246:1275-1281.   |
| <input type="checkbox"/>                      | C80 | Ingber et al., (1990), "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," <u>Nature</u> , 348:555-557.  |
| <input type="checkbox"/>                      | C81 | Jones et al., (1986), "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <u>Nature</u> , 321:6069:522-525.   |
| <input type="checkbox"/>                      | C82 | Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2," <u>Journal of Biological Chemistry</u> , 262:12:5723-5731.  |
| <input type="checkbox"/>                      | C83 | Jung et al., (1986), "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of target cells coated with anti-target-anti-T3 conjugates," <u>Proc. Natl. Acad. Sci.</u> , 83:4479-4483.  |
| <input type="checkbox"/>                      | C84 | Junghans et al., (1996), "The protection receptor of IgG catabolism is the B2-microglobulin-containing neonatal intestinal transport receptor," <u>Proc. Natl. Acad. Sci.</u> , 93:11:5512-5516.   |
| <input type="checkbox"/>                      | C85 | Kang et al., (1991), "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," <u>Proc. Natl. Acad. Sci.</u> , 88:11:1120-11123.  |
| <input type="checkbox"/>                      | C86 | Kappel et al., (1992), "Regulating gene expression in transgenic animals," <u>Current Opinion in Biotechnology</u> , 3:548-553.  |
| <input type="checkbox"/>                      | C87 | Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFcγ Receptor Antibodies," <u>Journal of Experimental Medicine</u> , 160:6:1686-1701.   |
| <input checked="" type="checkbox"/>           | C88 | Kim et al., (1997), "An Ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production," <u>Journal Immunology</u> , 158:9:4137-4144. |

EXAMINER

David A. Savender

DATE CONSIDERED

4/26/04

RECEIVED  
NOV 10 2003  
TECH CENTER  
1600/2900



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 12 OF 16

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

|   |      |  |
|---|------|--|
| ✓ | C89  | Kim et al., (1999), "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV," <u>Journal of Interferon and Cytokine Research</u> , 19:77-84.                       |
| ✓ | C90  | Kranz et al., (1984), "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes," <u>Proc. Natl. Acad. Sci.</u> , 81:7922-7926.             |
| ✓ | C91  | Kuo et al., (2001), "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," <u>Journal of Cell Biology</u> , 152:6:1233-1246.                                |
| ✓ | C92  | LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <u>Journal of Biological Chemistry</u> , 268:31:23311-23317.                             |
| ✓ | C93  | Lazar et al., (1988), "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Molecular and Cellular Biology</u> , 8:3:1247-1252.           |
| ✓ | C94  | LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <u>Cancer Research</u> , 51:2694-2698.  |
| ✓ | C95  | Lieschke, et al., (1997), "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo," <u>Nature Biotechnology</u> , 15:1:35-40.   |
| ✓ | C96  | Linsley et al., (1991), "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," <u>Journal of Experimental Medicine</u> , 174:3:561-569.   |
| ✓ | C97  | Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes," <u>Proc. Natl. Acad. Sci.</u> , 82:8648-8652.   |
| ✓ | C98  | Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," <u>Science</u> , 239:395-398.   |
| ✓ | C99  | Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , 91:10:3730-3736.        |
| ✓ | C100 | Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells," <u>Protein Engineering</u> , 11:6:495-500.  |
| ✓ | C101 | Lode et al., (1998), "Immunocytokines: a promising approach to cancer immunotherapy," <u>Pharmacol. Ther.</u> , 80:3:277-292.  |
| ✓ | C102 | Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," <u>Blood</u> , 91:5:1706-1715.   |
| ✓ | C103 | Lode et al., (1999), "Synergy between an antiangiogenic integrin $\alpha_v$ antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," <u>Proc. Natl. Acad. Sci.</u> , 96:1591-1596. |
| ✓ | C104 | Lode et al., (1999), "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," <u>Proc. Natl. Acad. Sci.</u> , 96:8591-8596.                                    |
| ✓ | C105 | Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," <u>Immunological Investigations</u> , 29:2:117-120.   |

EXAMINER

David A. Saunders

DATE CONSIDERED

2/26/04

RECEIVED  
NOV 10 2003  
TECH CENTER 1600/2900



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 13 OF 16

|  |      |   |
|--|------|---|
| FORM PTO - 1449                                  |      | ATTORNEY DOCKET NO.: LEX-011 (4006/23)  |
| SUPPLEMENTAL INFORMATION<br>DISCLOSURE STATEMENT |      | APPLICANT(S): Gillies et al.  |
|  |      | SERIAL NO.: 09/780,668      CONF.: 8264   |
|  |      | FILING DATE: February 09, 2001      GROUP: 1644   |
| gus  | C106 | Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," <u>Blood</u> , 84:2457-2466.             |
|  | C107 | Mark et al., (1992), "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins," <u>Journal of Biological Chemistry</u> , 267:36:26166-26171.   |
|  | C108 | Martinotti et al., (1995), "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," <u>Eur. J. Immunol.</u> 25:137-146.                          |
|  | C109 | Medesan et al., (1997), "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1," <u>J. Immunology</u> , 158:5:2211-2217.   |
|  | C110 | Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of Cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," <u>Cancer Research</u> , 57:2890-2895.                                      |
|  | C111 | Mosmann et al., (1989), "TH1 and TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," <u>Ann. Rev. Immunol.</u> 7:145-173.   |
|  | C112 | Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> 247:979-994.  |
|  | C113 | Mullins et al., (1998), "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation," <u>Immunopharmacol. Immunotoxicol.</u> 20:4:473-492.  |
|  | C114 | Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related $\alpha$ -melanocyte-stimulating hormone fusion protein," <u>Proc. Natl. Acad. Sci.</u> 83:8258-8262. |
|  | C115 | Murphy, (1988), "Diphtheria-related peptide hormone gene fusions: A molecular gene approach to chimeric toxin development," <u>Immunotoxins</u> , 123-140.  |
|  | C116 | Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," <u>Nucleic Acids Research</u> , 13:17:6361-6373.  |
|  | C117 | Netti et al., (1995), "Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery," <u>Cancer Research</u> , 55:5451-5458.  |
|  | C118 | Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," <u>Proc. Nat. Acad. Sci.</u> 96:3137-3142.  |
|  | C119 | Neuberger et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," <u>Nature</u> , 312:604-608.  |
|  | C120 | O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> , 79:315-328.   |
|  | C121 | O'Reilly et al., (1996), "Angiostatin induces and sustains dormancy of human primary tumors in mice," <u>Nature Medicine</u> , 2:6:689-692.   |

RECEIVED  
NOV 10 2003  
TECH CENTER 1600/2800

|                                   |                                |
|-----------------------------------|--------------------------------|
| EXAMINER <i>David A. Saunders</i> | DATE CONSIDERED <i>2/26/04</i> |
|-----------------------------------|--------------------------------|



FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

|    |      |   |
|----|------|---|
| 28 | C122 | O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <u>Cell</u> , 88:277-285.  |
|    | C123 | Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins," <u>Journal of Biological Chemistry</u> , 264:26:15157-15160.  |
|    | C124 | Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , 6:407-438.  |
|    | C125 | Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies," <u>J. Exp. Medicine</u> , 163:166-178.                              |
|    | C126 | Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," <u>Journal of Immunology</u> , 142:10:3662-3667.   |
|    | C127 | Polizzi et al., (1999), "A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts," <u>Cancer Research</u> , 59:1036-1040.   |
|    | C128 | Putzer et al., (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," <u>Proc. Nat'l Acad. Sci.</u> , 94:20:10889-10894.                    |
|    | C129 | Reisfeld et al., (1996), "Recombinant antibody fusion proteins for cancer immunotherapy," <u>Current Topics in Microbiology and Immunology</u> , 27-53.   |
|    | C130 | Reisfeld et al., (1997), "Immunocytokines: a new approach to immunotherapy of melanoma," <u>Melanoma Research</u> , 7:2:S99-S106.   |
|    | C131 | Riethmuller et al., (1994), "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <u>The Lancet</u> , 343:1177-1183.  |
|    | C132 | Roessler et al., (1994), "Cooperative interactions between the interleukin 2 receptor $\alpha$ and $\beta$ chains alter the interleukin 2-binding affinity of the receptor subunits," <u>Proc. Natl. Acad. Sci.</u> , 91:3344-3347. |
|    | C133 | Roitt et al., (1993), "The Role of TH Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," <u>Immunology</u> , Third Edition, 8.3-8.4.  |
|    | C134 | Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: current status and future prospects," <u>Immunology Today</u> , 9:2:58-62.   |
|    | C135 | Rozwarski et al., (1994), "Structural comparisons among the short-chain helical cytokines," <u>Structure</u> , 2:3:159-173.   |
|    | C136 | Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," <u>Cancer Research</u> , 46:4701-4705.   |
|    | C137 | Sasaki et al., (1998), "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," <u>The EMBO Journal</u> , 17:15:4249-4256.                       |
| ✓  | C138 | Sauve et al., (1991), "Localization in human interleukin 2 of the binding site of the $\alpha$ chain (p55) of the interleukin 2 receptor," <u>Proc. Natl. Acad. Sci.</u> , 88:4636-4640.  |


RECEIVED  
NOV 10 2003  
TECH CENTER 1600/2800

EXAMINER

David A. Saunders

DATE CONSIDERED

2/26/04



|   |      |   |
|---|------|---|
| FORM PTO - 1449                               |      | ATTORNEY DOCKET NO.: LEX-011 (4006/23)  |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT |      | APPLICANT(S): Gillies et al.  |
|   |      | SERIAL NO.: 09/780,668 CONF.: 8264  |
|   |      | FILING DATE: February 09, 2001 GROUP: 1644  |
| <i>guf</i>                                    | C139 | Schnee et al., (1987), "Construction and expression of a recombinant antibody-targeted plasminogen activator," <u>Proc. Natl. Acad. Sci.</u> , 84:6904-6908.  |
|   | C140 | Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," <u>Journal of Immunology</u> , 148:11:3433-3340.   |
|   | C141 | Senter et al., (1988), "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with ectoposide phosphate," <u>Proc. Natl. Acad. Sci.</u> , 85:13:4842-4846.  |
|   | C142 | Shanafelt et al., (2000), "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo," <u>Nature Biotechnology</u> , 18:1197-1202.   |
|   | C143 | Sharma et al., (1999), "T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function," <u>Journal of Immunology</u> , 163:5020-5028.  |
|   | C144 | Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon- $\lambda$ and is not blocked by human IgG," <u>Journal of Immunology</u> , 137:11:3378-3382. |
|   | C145 | Shiff et al., (1995), "Sulindac Sulfide, an Aspirin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," <u>Journal of Clinical Investigation</u> , 96:491-503.   |
|   | C146 | Shin et al., (1990), "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting," <u>Proc. Natl. Acad. Sci.</u> , 87:5322-5326.  |
|   | C147 | Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," <u>Cancer Research</u> , 57:1329-1334.   |
|   | C148 | Stevenson et al., (1997), "Conjugation of Human Fc $\gamma$ in Closed-Hinge or Open-Hinge Configuration to Fab $\gamma$ and Analogous Ligands," <u>Journal of Immunology</u> , 158:2242-2250.   |
|   | C149 | Sulitzeanu et al., (1993), "Immunosuppressive factors in human cancer," <u>Adv. Cancer Research</u> , 60:247-267.   |
|   | C150 | Taniguchi et al., (1983), "Structure and expression of a cloned cDNA for human interleukin-2," <u>Nature</u> , 302:305-309.   |
|   | C151 | Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <u>Journal of Immunology</u> , 143:8:2595-2601.  |
|   | C152 | Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," <u>Journal of Experimental Medicine</u> , 178:2:661-667.   |
|   | C153 | Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," <u>Int. J. Cancer</u> , 57:920-925.  |
|   | C154 | <u>The Merck Manual of Diagnosis and Therapy</u> , 990-993, 1278-1283 (17 <sup>th</sup> ed. 1999).  |
| <i>✓</i>                                      | C155 | Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," <u>Cancer Research</u> , 48:5:1119-1123  |

EXAMINER

*Daniel A. Spencer*

DATE CONSIDERED

*2/26/04*RECEIVED  
NOV 10 2003  
TECH CENTER 1600/23



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 16 OF 16

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

|   |      |  |
|---|------|--|
| ✓ | C156 | Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," <u>Science</u> , 242:1166-1168   |
| ✓ | C157 | Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," <u>Blood</u> , 84:4008-4027.                       |
| ✓ | C158 | Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," <u>Cancer Research</u> , 56:467-470.   |
| ✓ | C159 | Varki et al., (1984), "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," <u>Cancer Research</u> , 44:681-687.  |
| ✓ | C160 | Verhoeven et al., (1988), "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>Science</u> , 239:1534-1536.   |
| ✓ | C161 | Villunger et al., (1997), "Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance," <u>Blood</u> , 90:1:12-20.                                |
| ✓ | C162 | Watanabe et al., (1997), "Long-term depletion of naive T cells in patients treated for Hodgkin's disease," <u>Blood</u> , 90:9:3662-3672.  |
| ✓ | C163 | Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," <u>Blood</u> , 82:1507-1516.  |
| ✓ | C164 | Williams et al., (1986), "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment," <u>Gene</u> , 43:319-324.  |
| ✓ | C165 | Williams et al., (1987), "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein," <u>Protein Engineering</u> , 1:6:493-498. |
| ✓ | C166 | Wooley et al., (1993), "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor 1c Fusion Protein on Type II Collagen-Induced Arthritis in Mice," <u>Journal Immunology</u> , 151: 6602-6607.                                  |
| ✓ | C167 | Wu et al., (1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin," <u>Biochemical and Biophysical Research Communications</u> , 236:651-654.  |
| ✓ | C168 | Xiang et al., (1997), "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," <u>Cancer Research</u> , 57:4948-4955.  |
| ✓ | C169 | Zheng et al., (1995), "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation," <u>Journal of Immunology</u> , 154:5590-5600.                                |
| ✓ | C170 | Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," <u>J. Biol. Chem.</u> , 269:3469-3474.  |

2698127

EXAMINER

David A. Saunders

DATE CONSIDERED

2/26/04

RECEIVED  
NOV 10 2003  
TECH CENTER 1800/2800





FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

## U.S. PATENT DOCUMENTS

| EXAM.<br>INT.    |     | DOCUMENT<br>NUMBER   | DATE              | NAME                           | CLASS          | SUB<br>CLASS     | FILING DATE IF<br>APPROPRIATE |
|------------------|-----|----------------------|-------------------|--------------------------------|----------------|------------------|-------------------------------|
| <i>of record</i> | A60 | 4,703,008            | 10/27/87          | Lin                            | 435            | 240.2            | 11/30/84                      |
|                  | A61 | 5,457,038            | 10/10/95          | Trinchieri <i>et al.</i>       | 435            | 69.52            | 9/18/90                       |
|                  | A62 | 5,441,868            | 8/15/95           | Lin                            | 435            | 69.4             | 10/23/87                      |
|                  | A63 | 5,547,933            | 8/20/96           | Lin                            | 514            | 8                | 6/7/95                        |
|                  | A64 | 5,618,698            | 4/8/97            | Lin                            | 435            | 69.4             | 6/6/95                        |
|                  | A65 | 5,650,150            | 7/22/97           | Gillies                        | 424            | 134.1            | 7/27/94                       |
|                  | A66 | 5,688,679            | 11/18/97          | Powell                         | 435            | 240.2            | 10/6/93                       |
|                  | A67 | 5,723,125            | 3/3/98            | Chang <i>et al.</i>            | 424            | 134.1            | 9/25/96                       |
|                  | A68 | 5,756,349            | 5/26/98           | Lin                            | 435            | 325              | 6/6/95                        |
|                  | A69 | <del>5,908,626</del> | <del>6/1/99</del> | <del>Chang <i>et al.</i></del> | <del>424</del> | <del>134.1</del> | <del>12/19/97</del>           |
|                  | A70 | 5,955,422            | 9/21/99           | Lin                            | 514            | 8                | 8/2/93                        |
|                  | A71 | 6,100,387            | 8/8/00            | Herrmann <i>et al.</i>         | 536            | 23.4             | 2/28/97                       |
|                  | A72 | 6,231,536            | 5/15/01           | Lentz                          | 604            | 5.04             | 5/21/99                       |
|                  | A73 | 6,284,536            | 9/4/01            | Morrison <i>et al.</i>         | 435            | 328              | 4/20/99                       |
|                  | A74 | 6,335,176 B1         | 1/1/02            | Inglese <i>et al.</i>          | 435            | 7.72             | 10/16/98                      |
|                  | A75 | 6,340,742            | 1/22/02           | Burg <i>et al.</i>             | 530            | 351              | 6/28/00                       |
|                  | A76 | 6,444,792            | 9/3/02            | Gray <i>et al.</i>             | 530            | 387.3            | 1/8/99                        |
|                  | A77 | 6,475,717 B1         | 11/5/02           | Enssle <i>et al.</i>           | 435            | 5                | 7/25/97                       |
|                  | A78 | 6,485,726 B1         | 11/26/02          | Blumberg <i>et al.</i>         | 424            | 178.1            | 7/24/98                       |
|                  | A79 | 6,506,405            | 1/14/03           | Desai <i>et al.</i>            | 424            | 450              | 8/1/00                        |
|                  | A80 | 6,583,272            | 6/24/03           | Bailon                         | 530            | 397              | 6/27/00                       |
|                  | A81 | 6,586,398            | 7/1/03            | Kinstler <i>et al.</i>         | 514            | 12               | 4/7/00                        |
|                  | A82 | 6,617,135            | 9/9/03            | Gillies <i>et al.</i>          | 435            | 69.7             | 8/9/00                        |
|                  | A83 | 2001/0053539 A1      | 12/20/01          | Lauffer <i>et al.</i>          | 435            | 69.1             | 4/6/99                        |

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/6/05*



FORM PTO-1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

## U.S. PATENT DOCUMENTS

| EXAM.<br>INIT. |     | DOCUMENT<br>NUMBER | DATE     | NAME                   | CLASS | SUB<br>CLASS | FILING DATE IF<br>APPROPRIATE |
|----------------|-----|--------------------|----------|------------------------|-------|--------------|-------------------------------|
| <i>dy</i>      | A84 | 2002/0081664 A1    | 6/27/02  | Lo <i>et al.</i>       | 435   | 69.5         | 10/11/01                      |
|                | A85 | 2002/0142374 A1    | 10/3/02  | Gallo <i>et al.</i>    | 435   | 69.1         | 8/17/99                       |
|                | A86 | 2002/0147311 A1    | 10/10/02 | Gillies <i>et al.</i>  | 530   | 387.1        | 2/9/01                        |
|                | A87 | 2002/0192222 A1    | 12/19/02 | Blumberg <i>et al.</i> | 424   | 178.1        | 8/8/02                        |
|                | A88 | 2002/0193570 A1    | 12/19/02 | Gillies <i>et al.</i>  | 530   | 351          | 12/4/01                       |
|                | A89 | 2003/0003529 A1    | 1/2/03   | Bayer                  | 435   | 68.1         | 7/19/02                       |
|                | A90 | 2003/0044423 A1    | 3/6/03   | Gillies <i>et al.</i>  | 424   | 192.1        | 3/7/02                        |
|                | A91 | 2003/0049227 A1    | 3/13/03  | Gillies <i>et al.</i>  | 424   | 85.1         | 6/29/01                       |
|                | A92 | 2003/0105294 A1    | 6/5/03   | Gillies <i>et al.</i>  | 530   | 351          | 2/24/99                       |
|                | A93 | 2003/0012789 A1    | 1/6/03   | Blumberg <i>et al.</i> | 424   | 145.1        | 8/8/02                        |
|                | A94 | 2003/0157054 A1    | 8/21/03  | Gillies <i>et al.</i>  | 424   | 85.1         | 5/3/02                        |
|                | A95 | 2003/0166163 A1    | 9/4/03   | Gillies                | 435   | 69.52        | 12/4/02                       |
|                | A96 | 2003/0166877 A1    | 9/4/03   | Gillies <i>et al.</i>  | 530   | 395          | 3/29/02                       |

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/7/05*



FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

## FOREIGN PATENT DOCUMENTS

| EXAM<br>INIT. | DOCUMENT<br>NUMBER | DATE            | COUNTRY<br>CODE | CLASS | SUB<br>CLASS | FILING<br>DATE | ABSTRACT<br>ONLY | ENGLISH<br>LANG<br>(Y/N) |
|---------------|--------------------|-----------------|-----------------|-------|--------------|----------------|------------------|--------------------------|
| <i>ds</i>     | B92                | 1 088 888 A1    | 4/04/01         | EP    |              | 5/13/99        | N                | Y                        |
| <i>ds</i>     | B93                | WO 96/18412     | 6/20/96         | PCT   |              | 12/12/94       | N                | Y                        |
| <i>ds</i>     | B94                | WO 97/00319     | 1/03/97         | PCT   |              | 6/11/96        | N                | Y                        |
| <i>ds</i>     | B95                | WO 99/43713     | 9/02/99         | PCT   |              | 2/24/99        | N                | Y                        |
| <i>ds</i>     | B96                | WO 00/24893     | 5/04/00         | PCT   |              | 10/18/99       | N                |                          |
|               | B97                | WO 01/36489 A2  | 5/25/01         | PCT   |              | 11/03/00       | N                | Y                        |
|               | B98                | WO 01/58957 A2  | 8/16/01         | PCT   |              | 2/09/01        | N                | Y                        |
|               | B99                | WO 02/02143 A2  | 1/10/02         | PCT   |              | 06/29/01       | N                | Y                        |
|               | B100               | WO 02/066514 A2 | 8/29/02         | PCT   |              | 2/18/02        | Y                | Y                        |
|               | B101               | WO 02/072605 A2 | 9/19/02         | PCT   |              | 3/07/02        | N                | Y                        |
|               | B102               | WO 02/079232 A2 | 10/10/02        | PCT   |              | 3/30/02        | N                | Y                        |
|               | B103               | WO 02/079415 A2 | 10/10/02        | PCT   |              | 3/29/02        | N                | Y                        |
|               | B104               | WO 02/090566 A2 | 11/14/02        | PCT   |              | 5/03/02        | N                | Y                        |
|               | B105               | WO 03/048334 A2 | 6/12/03         | PCT   |              | 12/04/02       | N                | Y                        |
| <i>ds</i>     | B106               | WO 03/077834 A2 | 9/25/03         | PCT   |              | 7/03/02        | N                | Y                        |

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/6/05*



|   |   |   |  |
|---|---|---|--|
| <b>FORM PTO - 1449</b>                                      |   | <b>ATTORNEY DOCKET NO.: LEX-011</b>   |  |
| <b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> |   | <b>APPLICANT(S): Gillies <i>et al.</i></b>  |  |
|   |   | <b>SERIAL NO.: 09/780,668</b>   |  |
|   |   | <b>EXAMINER: David A. Saunders</b>  |  |
|   |   | <b>FILING DATE: February 9, 2001 GROUP: 1644</b>  |  |
| <b>EXAM. INIT.</b>  | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b> |   |  |
| <i>gus</i>  | C171  | Angal et al., (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <u>Molecular Immunology</u> , 30:105-108.   |  |
|   | C172  | Balova et al., (1999), "The Ch 14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , 5:4259-4263. |  |
|   | C173  | Becker et al., (1996), "Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy," <u>J Clin Invest</u> , 98(12):2801-4.   |  |
|   | C174  | Becker et al., (1996), "T Cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy," <u>J Exp Med</u> , 183(50):2361-6.  |  |
|   | C175  | Bitonti et al., (2002), "Transépithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," <u>Respiratory Drug Delivery</u> , 8:309-312.  |  |
|   | C176  | Briggs et al., (1974), "Hepatic Clearance of Intact and desialylated Erythropoietin," <u>American Journal of Physiology</u> , 227:1385-1388.  |  |
|   | C177  | Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291.   |  |
|   | C178  | Cruse et al., (1995), <u>Illustrated Dictionary of Immunology</u> , CRC Press, NY, p.156-7.   |  |
|   | C179  | Darling et al., (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," <u>Biochemistry</u> , 41:14524-14531.  |  |
|   | C180  | Davis et al., (2003), "Immunocytokines: amplification of anti-cancer immunity," <u>Cancer Immunol Immunother</u> 52:297-308   |  |
|   | C181  | Dolman et al., (1998), "Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy," <u>Clin Cancer Res</u> , 4(10):2551-7.                           |  |
|   | C182  | Duncan et al., (1988), "The binding site for C1q on IgG," <u>Nature</u> , 332:738-740.  |  |
|   | C183  | Egrie et al., (2001), "Development and characterization of novel erythropoiesis stimulating protein (NESP)," <u>Nephrol. Dial. Transplant</u> , 16:3-13.  |  |
|   | C184  | Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502.   |  |
|   | C185  | Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric (Fab') with Specificity for Carcinomas and Human IL-2," <u>The J. of Immunology</u> , 146:72446-2452.              |  |

|                                   |                               |
|-----------------------------------|-------------------------------|
| EXAMINER <i>David A. Saunders</i> | DATE CONSIDERED <i>7/6/05</i> |
|-----------------------------------|-------------------------------|

DUPLICATE  
OF C43



FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

| EXAM.<br>INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |  |
|----------------|--|--|
|                | C186   | Fibi et al., (1995), "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," <u>Blood</u> , 85:1229-1236.   |
|                | C187   | Frost et al., (1997), "A Phase I/II Trial of Murine Monoclonal Anti-GD2 Antibody 14.G2a plus Interleukin-2 Children with Refractory Neuroblastoma", <u>Cancer</u> , 80:317-33.   |
|                | C188   | Gao et al., (1999), "Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins," <u>Clin Diagn Lab Immunol.</u> , 6(2):236-42.   |
|                | C189   | Gillies et al., (1991), "Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody," <u>Hybridoma</u> , 10(3):347-56.  |
|                | C190   | Gillies et al., (1999), "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," <u>Cancer Research</u> , 59:2159-2166.   |
|                | C191   | Gillies et al., (2002), "Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer," <u>Cancer Immunol Immunother.</u> , 51(8):449-60.   |
|                | C192   | Gillies et al., (2002), "Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis," <u>Clin. Cancer Res.</u> , 8(1):210-6.   |
|                | C193   | Greene et al., (1975), "Neuronal properties of hybrid neuroblastoma X sympathetic ganglion cells", <u>Proc. Natl. Acad. Sci. USA</u> , 72:4923-4927.   |
|                | C194   | Hammerling et al., (1996), "In vitro bioassay for human erythropoietin based on proliferative stimulation of an erythroid cell line and analysis of carbohydrate-dependent microheterogeneity," <u>Journal of Pharmaceutical and Biomedical Analysis</u> , 14:1455-1469. |
|                | C195   | Hank et al., (2003), "Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine," <u>Methods Mol Med.</u> , 85:123-31.  |
|                | C196   | Haraguchi, (1994), "Isolation of GD3 synthase gene by expression cloning of GM3 $\alpha$ -2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-9.  |
|                | C197   | Harris, (1995), "Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture," <u>J. Chromatogr. A</u> , 705:129-134.   |
|                | C198   | Hezareh et al, (2001), "Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1," <u>J. Virol.</u> , 75(24):12161-8.   |
|                | C199   | Idusogie et al., (2000), "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," <u>J. Immunol.</u> , 164(8):4178-84.  |
|                | C200   | Imboden et al., (2001), "The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy," <u>Cancer Res.</u> , 61(4):1500-7.   |

|                                   |                               |
|-----------------------------------|-------------------------------|
| EXAMINER <i>David A. Saunders</i> | DATE CONSIDERED <i>7/6/05</i> |
|-----------------------------------|-------------------------------|



FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

| EXAM.<br>INT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)   |
|---------------|--|
| <i>dal</i>    | C201 Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527.  |
|               | C203 Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26:126-131.  |
|               | C204 Kendra et al., (1999), "Pharmacokinetics and Stability of the ch 14.18-Interleukin-2 Fusion Protein in Mice," <u>Cancer Immunol. Immunotherapy</u> , 48:219-229.  |
|               | C205 King et al., (2003), "A Phase I/II clinical trial of the immunocytokine hu14.18-IL2 (EMD 273063) in patients with melanoma," Author's manuscript dated June 6, 2003.  |
|               | C206 Kitamura et al., (1989), "Establishment and Characterization of a Unique Human Cell Line that Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," <u>Journal of Cellular Physiology</u> , 140:323-334.  |
|               | C207 Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma", <u>J. Clin. Oncol.</u> , 19:4189-94.   |
|               | C208 Locatelli et al., (2001), "Darbepoetin alfa Amgen," <u>Current Opinion in Investigational Drugs</u> , 2:1097-1104.  |
|               | C209 Lode et al., (1997), "Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow," <u>J Natl Cancer Inst.</u> , 89(21):1586-94.   |
|               | C210 Lode et al., (2000), "What to do with targeted IL-2," <u>Drugs Today</u> , 36(5):321-36.  |
|               | C211 Lode et al., (2000), "Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction," <u>J. Clin. Invest.</u> , 105(11):1623-30.   |
|               | C212 Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant.</u> , 17:66-70.   |
|               | C213 Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis," <u>Blood</u> , 99(11):4166-73. |
|               | C214 Mueller et al., (1997), "Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells," <u>Molecular Immunology</u> , 34(6):441-452.   |
|               | C215 Mullins et al., (1997), "Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities," <u>Cancer Immunol Immunother.</u> , 45:20-28.  |
| <i>↓</i>      | C216 Naramura et al., "Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells," <u>Immunol Lett.</u> , 39(1):91-9.   |

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/16/05*



FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

| EXAM.<br>INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)   |
|----------------|--|
| <i>del</i>     | C217 Neal et al., (2003), "NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy," <u>Cancer Immunol Immunother.</u> , Pub. Med ID: 14504825.   |
|                | C218 Ngo et al., (1994), "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox" pp. 433-440 and 492-495.  |
|                | C219 Niethammer et al., (2001) "An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevent growth and dissemination of Lewis Lung carcinoma in CEA transgenic mice," <u>Vaccine</u> , 20(3-4):421-9.   |
|                | C220 Niethammer et al., (2001) "Targeted Interleukin 2 therapy enhances protective immunity induced by an autologous murine melanoma," <u>Cancer Res.</u> , 61(16):6178-84.  |
|                | C221 Nimitz et al., (1993) Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56.  |
|                | C222 Pancook et al., (1996), "Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2," <u>Cancer Immunol Immunother.</u> , 42(2):88-92.  |
|                | C223 Park et al., (2000), "Efficiency of promoter and cell line in high-level expression of erythropoietin," <u>Biotechnol. Appl. Biochem.</u> , 32:167-172.   |
|                | C224 Reisfeld et al., (1996), "Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy," <u>J Clin Lab Anal.</u> , 10(3):160-6.   |
|                | C225 Reisfeld et al., (1996), "Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein," <u>Cancer Res.</u> , 56(8):1707-12.  |
|                | C226 Ruchtmann et al., (2001), "MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma," <u>Cancer Res.</u> , 61(23):8498-503.   |
|                | C227 Sabzevari et al., (1994), "A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human severe combined immunodeficiency mice," <u>Proc Natl Acad Sci USA</u> , 91(20):9626-30.   |
|                | C228 Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of controlled Clinical Trials," <u>Journal of National Cancer Institute</u> , 93:1204-1214.  |
|                | C229 Shinkawa et al., (2003), "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity", <u>J. Biol. Chem.</u> , 278:3466-3473. |
| ✓              | C230 Spickermann et al., (2002), "Receptor-mediated immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung," <u>J. Exp. Med.</u> , 196:303-310.   |

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/6/05*



FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

| EXAM.<br>INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |   |
|----------------|--|---|
| <i>Yes</i>     | C231   | Strom et al., (1996), "Therapeutic Approach to Organ Transplantation", <u>Blackwell Science</u> , Chapter 36, pp. 451-456.  |
|                | C232   | Syed et al., (1998), "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," <u>Nature</u> , 395:511-516.  |
|                | C233   | Thommesen et al., (2000), "Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation", <u>Mol. Immunol.</u> , 37(16):995-1004.  |
|                | C234   | Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517.   |
|                | C235   | Xiang et al., (1998), "Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases," <u>Cancer Res.</u> , 58(17):3918-25.   |
|                | C236   | Xiang et al., (1999) "T Cell memory against colon carcinoma is long-lived in the absence of antigen," <u>J Immunol.</u> , 163(7):3676-83.   |
|                | C237   | Xiang et al., (2001), "A dual function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice," <u>J Immunol.</u> , 167(8):4560-5. |
|                | C238   | Xiang et al., (2001), "Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice," <u>Clin Cancer Res.</u> , 7(3 Suppl):856s-864s.   |
|                | C239   | Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.8 in Patients With Refractory Neuroblastoma and Osteosarcoma", <u>J. Clin. Oncol.</u> , 16:2169-80.  |
| <i>✓</i>       | C240   | Zagorazon et al., (1999), "Potentiation of antitumor effect of IL-12 in combination with paclitaxel in murine melanoma model in vivo," <u>International Journal of Molecular Medicine</u> , 4:645-648.  |

3025201\_1

|                                   |                               |
|-----------------------------------|-------------------------------|
| EXAMINER <i>David A. Saunders</i> | DATE CONSIDERED <i>7/6/05</i> |
|-----------------------------------|-------------------------------|



IDS FILED 9/28/04

| FORM PTO - 1449                                     |      |                 |          |                   | ATTORNEY DOCKET NO.: LEX-011              |           |                            |               |                    |
|---|------|-----------------|----------|-------------------|---|-----------|----------------------------|---------------|--------------------|
| THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT |      |                 |          |                   | APPLICANT(S): Gillies et al.              |           |                            |               |                    |
|   |      |                 |          |                   | SERIAL NO.: 09/780,668                    |           |                            |               |                    |
|   |      |                 |          |                   | EXAMINER: David A. Saunders               |           |                            |               |                    |
|   |      |                 |          |                   | FILING DATE: February 9, 2001 GROUP: 1644 |           |                            |               |                    |
| U.S. PATENT DOCUMENTS                               |      |                 |          |                   |   |           |                            |               |                    |
| EXAM. INT.  |      | DOCUMENT NUMBER | DATE     | NAME              | CLASS                                     | SUB CLASS | FILING DATE IF APPROPRIATE |               |                    |
| <i>OK</i>   | A97  | 5,601,819       | 2/11/97  | Wong et al.       | —   | —         |                            |               |                    |
|   | A98  | 5,891,680       | 4/6/99   | Lieschke et al.   | —   | —         |                            |               |                    |
|   | A99  | 5,994,104       | 11/30/99 | Anderson et al.   | —   | —         |                            |               |                    |
|   | A100 | 6,429,199       | 8/6/02   | Krieg et al.      | —   | —         |                            |               |                    |
|   | A101 | 6,500,641       | 12/31/02 | Chen et al.       | —   | —         |                            |               |                    |
|   | A102 | 6,551,592       | 4/22/03  | Lindhofer et al.  | —   | —         |                            |               |                    |
|   | A103 | 6,646,113       | 11/11/03 | Dreyfuss et al.   | —   | —         |                            |               |                    |
|   | A104 | 2002/0037558    | 3/28/02  | Lo et al.         | —   | —         |                            |               |                    |
|   | A105 | 2002/0146388    | 10/10/02 | Gillies           | —   | —         |                            |               |                    |
|   | A106 | 2003/0139365    | 7/24/03  | Lo et al.         | —   | —         |                            |               |                    |
|   | A107 | 2003/0139575    | 7/24/03  | Gillies           | —   | —         |                            |               |                    |
|   | A108 | 2004/0013640    | 1/22/04  | Zardi et al.      | —   | —         |                            |               |                    |
|   | A109 | 2004/0033210    | 2/19/04  | Gillies           | —   | —         |                            |               |                    |
|   | A110 | 2004/0043457    | 3/4/04   | Schumacher et al. | —   | —         |                            |               |                    |
|   | A111 | 2004/0053366    | 3/18/04  | Lo et al.         | —   | —         |                            |               |                    |
|   | A112 | 2004/0072299    | 4/15/04  | Gillies et al.    | —   | —         |                            |               |                    |
| <i>✓</i>  | A113 | 2004/0082039    | 4/29/04  | Gillies et al.    | —   | —         |                            |               |                    |
| FOREIGN PATENT DOCUMENTS                            |      |                 |          |                   |   |           |                            |               |                    |
| EXAM. INT.  |      | DOCUMENT NUMBER | DATE     | COUNT RY CODE     | CLASS                                     | SUB CLASS | FILING DATE                | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
| <i>OK</i>   | B107 | WO 93/20185     | 10/14/93 | PCT               | —   | —         |                            |               |                    |
| EXAMINER <i>David A. Saunders</i>                   |      |                 |          |                   | DATE CONSIDERED <i>7/5/05</i>             |           |                            |               |                    |

**THIRD SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

APPLICANT(S): Gillies *et al.*




SERIAL NO.: 09/780,668


EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

| EXAM.<br>INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |  |
|----------------|--|--|
| <i>DS</i>      | C241   | Chapman et al., (1994), "Mapping Effector Functions of a Monoclonal Antibody to GD3 by Characterization of a Mouse-Human Chimeric Antibody," <u>Cancer Immuno. Immunother.</u> , 39:198-204.   |
|                | C242   | Conner et al., (2004), "Ex vivo Evaluation of Anti-EpCAM Immunocytokine huKS-IL2 in Ovarian Cancer," <u>J. Immunotherapy</u> , 27:211-219.   |
|                | C243   | de la Salle et al., (1996), "FcγR on Human Dendritic Cells," in <u>Human IgG Receptors</u> , pp. 39-55, van de Winkel et al. (eds.), R.G. Landes Co.   |
|                | C244   | Dorai et al., (1991), "Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Function," <u>Hybridoma</u> , 10(2):211-217.   |
|                | C245   | Dorai et al., (1992), "Role of Inter-Heavy and Light Chain Disulfide Bonds in the Effector Functions of Human IgG1," <u>Molecular Immunology</u> , 29(12):1487-1491.   |
|                | C246   | Elliott et al., (1996), "Fine-Structure Epitope Mapping of Antierythropoietin Monoclonal Antibodies Reveals a Model of Recombinant Human Erythropoietin Structure," <u>Blood</u> , 87(7):2702-2713.  |
|                | C247   | Gillies et al., (1991), "Targeting Human Cytotoxic T Lymphocytes to Kill Heterologous Epidermal Growth Factor Receptor-Bearing Tumor Cells: Tumor-Infiltrating Lymphocyte/Hormone Receptor/Recombinant Antibody," <u>J. Immunology</u> , 146(3):1067-1071.                           |
|                | C248   | Handgretinger et al., (1995), "A Phase I Study of Human/Mouse Chimeric Anti-ganglioside GD2 Antibody ch14.18 in Patients with Neuroblastoma," <u>European J. Cancer</u> , 31A(2):261-267.  |
|                | C249   | Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.18-IL2)," <u>Clin Cancer Research</u> , 2(12):1951-1959.  |
|                | C250   | Hurn et al., (1980), "Production of Reagent Antibodies," <u>Methods in Enzymology</u> , 70: 104-142.   |
|                | C251   | Isenman et al., (1975), "The Structure and Function of Immunoglobulin Domains: II. The Importance of Interchain Disulfide Bonds and the Possible Role of Molecular Flexibility in the Interaction between Immunoglobulin G and Complement," <u>J. Immunology</u> , 114(6):1726-1729. |
|                | C252   | Ko et al., (2004), "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocytokine EMD 273066 (huKS-IL2)," <u>J. Immunotherapy</u> , 27:232-239.  |
| <i>✓</i>       | C253   | Lo et al., (1992), "Expression and Secretion of an Assembled Tetrameric CH2-deleted Antibody in <i>E. Coli</i> ," <u>Hum. Antibod. Hybridomas</u> , 3:123-128.   |
| EXAMINER       | David A. Saunders  |  |
|                | DATE CONSIDERED  | 7/5/05   |



|   |   |  |  |
|---|---|--|--|
| <b>FORM PTO - 1449</b>  |   | <b>ATTORNEY DOCKET NO.: LEX-011</b>  |  |
| <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>  |   | <b>APPLICANT(S): Gillies <i>et al.</i></b>   |  |
|   |   | <b>SERIAL NO.: 09/780,668</b>  |  |
|   |   | <b>EXAMINER: David A. Saunders</b>   |  |
|   |   | <b>FILING DATE: February 9, 2001 GROUP: 1644</b>   |  |
| <b>EXAM. INIT.</b>  | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b> |  |  |
|                    | C254  | Maecker et al., (1997), "DNA Vaccination with Cytokine Fusion Constructs Biases the Immune Response to Ovalbumin," <u>Vaccine</u> , 15(15):1687-1696.  |  |
|   | C255  | Mueller et al., (1990), "Enhancement of Antibody-Dependent Cytotoxicity With A Chimeric Anti-GD2 Antibody," <u>J. Immunology</u> , 144(4):1382-1386  |  |
|   | C256  | Mueller et al., (1990), "Serum Half-Life and Tumor Localization of a Chimeric Antibody Deleted of the CH2 Domain and Directed Against the Disialoganglioside GD2," <u>Proc. Natl. Acad. Sci. USA</u> , 87:5702-5705.   |  |
|   | C257  | Naramura et al., (1993), "Therapeutic Potential of Chimeric and Murine Anti-(Epidermal Growth Factor Receptor) Antibodies in a Metastasis Model for Human Melanoma," <u>Cancer Immuno. Immunother.</u> , 37:343-349.   |  |
|   | C258  | Pertl et al., (2003), "Immunotherapy with a Posttranscriptionally Modified DNA Vaccine Induces Complete Protection Against Metastatic Neuroblastoma," <u>Blood</u> , 101(2):649-654.   |  |
|   | C259  | Reisfeld et al., (1994), "Potential of Genetically Engineered Anti-Ganglioside GD2 Antibodies for Cancer Immunotherapy," <u>Prog. Brain Res.</u> , 101:201-212   |  |
|   | C260  | Saleh et al., (1992), "Phase I Trial of the Chimeric Anti-GD2 Monoclonal Antibody ch14.18 in Patients With Malignant Melanoma," <u>Hum. Antib. Hybridomas</u> , 3:19-24.   |  |
|   | C261  | Sallusto et al., (1994), "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor $\alpha$ ," <u>J. Exp. Med.</u> , 179:1109-1118. |  |
|   | C262  | Schlom (1991), "Monoclonal Antibodies: They're More and Less Than You Think," in <u>Molecular Foundations of Oncology</u> , pp. 95-133.  |  |
|   | C263  | Weber et al., (2001), "Phase I Trial of huKS-IL2 Immunocytokine in Patients with Prostate Carcinoma: Clinical, PK, and Biological PD Results (Abstract)," <u>American Society of Clinical Oncology Program/Proceedings</u> , 20(Part 1):259a.  |  |
|   | C264  | Wen et al., (1994), "Erythropoietin Structure-Function Relationships: Identification of Functionally Important Domains," <u>J. Biological Chemistry</u> , 269(36):22839-22846.   |  |
|   | C265  | Gurewich et al., (1988), "Characterization of the Intrinsic Fibrinolytic Properties of Pro-urokinase through a Study of Plasmin-resistant Mutant Forms Produced by Site-specific Mutagenesis of Lysine <sup>158</sup> ," <u>J. Clin. Invest.</u> , 82:1956-1962.                       |  |
|                  | C266  | Miyake et al., (1988), "Synthesis of Recombinant Human Single-Chain Urokinase-Type Plasminogen Activator Variants Resistant to Plasmin and Thrombin," <u>J. Biochem.</u> , 104:643-647.  |  |
| <b>EXAMINER</b>  |   | <b>DATE CONSIDERED</b> 7/5/05  |  |




|  |   |   |                                      |
|--|---|---|--------------------------------------|
| <b>FORM PTO - 1449</b>                                     |   | <b>ATTORNEY DOCKET NO.: LEX-011</b>   |                                      |
| <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> |   | <b>APPLICANT(S): Gillies <i>et al.</i></b>  |                                      |
|  |   | <b>SERIAL NO.: 09/780,668</b>   |                                      |
|  |   | <b>EXAMINER: David A. Saunders</b>  |                                      |
|  |   | <b>FILING DATE: February 9, 2001 GROUP: 1644</b>  |                                      |
| <b>EXAM. INIT.</b>   | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b> |   |                                      |
| <i>David</i>   | C267  | Nelles et al., (1987), "Characterization of Recombinant Human Single Chain Urokinase-type Plasminogen Activator Mutants Produced by Site-specific Mutagenesis of Lysine <sup>158</sup> ," <u>The Journal of Biological Chemistry</u> , 262(12):5682-5689. |                                      |
| <b>EXAMINER</b>  | <i>David A. Saunders</i>  |   | <b>DATE CONSIDERED</b> <i>7/5/05</i> |

3113305\_1

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## U.S. PATENT DOCUMENTS

| EXAM.<br>INIT. |      | DOCUMENT<br>NUMBER | DATE     | NAME                     | CLASS | SUB<br>CLASS | FILING DATE<br>IF<br>APPROPRIATE |
|----------------|------|--------------------|----------|--------------------------|-------|--------------|----------------------------------|
| <i>dal</i>     | A114 | 4,522,811          | 6/11/85  | Eppstein <i>et al.</i>   | —     | —            |                                  |
| <i>lc</i>      | A115 | 4,667,016          | 5/19/87  | Lai <i>et al.</i>        | —     | —            |                                  |
|                | A116 | 4,732,683          | 3/22/88  | Georgiades <i>et al.</i> | —     | —            |                                  |
|                | A117 | 4,737,462          | 4/12/88  | Mark <i>et al.</i>       | —     | —            |                                  |
|                | A118 | 4,975,369          | 12/4/90  | Beavers <i>et al.</i>    | —     | —            |                                  |
|                | A119 | 5,082,658          | 1/21/92  | Palladino                | —     | —            |                                  |
|                | A120 | 5,091,513          | 2/25/92  | Huston <i>et al.</i>     | —     | —            |                                  |
|                | A121 | 5,399,346          | 3/21/95  | Anderson <i>et al.</i>   | —     | —            |                                  |
|                | A122 | 5,428,130          | 6/27/95  | Capon <i>et al.</i>      | —     | —            |                                  |
|                | A123 | 5,480,981          | 1/2/96   | Goodwin <i>et al.</i>    | —     | —            |                                  |
|                | A124 | 5,589,466          | 12/31/96 | Felgner <i>et al.</i>    | —     | —            |                                  |
|                | A125 | 5,614,184          | 3/25/97  | Sytkowski <i>et al.</i>  | —     | —            |                                  |
|                | A126 | 5,712,120          | 1/27/98  | Rodriguez <i>et al.</i>  | —     | —            |                                  |
|                | A127 | 5,738,852          | 4/14/98  | Robinson <i>et al.</i>   | —     | —            |                                  |
|                | A128 | 5,795,779          | 8/18/98  | McCormick <i>et al.</i>  | —     | —            |                                  |
|                | A129 | 5,827,703          | 10/27/98 | Debs <i>et al.</i>       | —     | —            |                                  |
|                | A130 | 5,837,821          | 11/17/98 | Wu <i>et al.</i>         | —     | —            |                                  |
|                | A131 | 5,888,773          | 3/30/99  | Jost <i>et al.</i>       | —     | —            |                                  |
|                | A132 | 6,281,010          | 8/28/01  | Gao <i>et al.</i>        | —     | —            |                                  |
|                | A133 | 6,291,158          | 9/18/01  | Winter <i>et al.</i>     | —     | —            |                                  |
|                | A134 | 6,627,615          | 9/30/03  | Debs <i>et al.</i>       | —     | —            |                                  |
| <i>↓</i>       | A135 | 2004/0180035       | 9/16/04  | Gillies <i>et al.</i>    | —     | —            |                                  |

EXAMINER


*David A. Saunders*

DATE CONSIDERED

*7/7/05*

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## FOREIGN PATENT DOCUMENTS

| EXAM<br>INIT. |      | DOCUMENT<br>NUMBER | DATE     | COUNTRY<br>CODE | CLASS | SUB<br>CLASS | FILING<br>DATE | ABSTRACT<br>ONLY | ENGLISH<br>LANG<br>(Y/N) |
|---------------|------|--------------------|----------|-----------------|-------|--------------|----------------|------------------|--------------------------|
| <i>gn</i>     | B108 | 0 344 134 B1       | 01/19/94 | EP              | —     | —            |                |                  |                          |
|               | B109 | 0 428 267 B1       | 12/11/96 | EP              | —     | —            |                |                  |                          |
|               | B110 | 0 428 596 B1       | 4/17/96  | EP              | —     | —            |                |                  |                          |
|               | B111 | 0 433 827 B1       | 3/14/98  | EP              | —     | —            |                |                  |                          |
|               | B112 | 0 519 596 A1       | 12/23/92 | EP              | —     | —            |                |                  |                          |
|               | B113 | 0 668 351 B1       | 9/22/99  | EP              | —     | —            |                |                  |                          |
|               | B114 | 0 699 755 B1       | 4/28/04  | EP              | —     | —            |                |                  |                          |
|               | B115 | 2 188 638 A        | 10/7/87  | GB              | —     | —            |                |                  |                          |
|               | B116 | WO 92/10755        | 6/25/92  | PCT             | —     | —            |                |                  |                          |
|               | B117 | WO 94/25609        | 11/10/94 | PCT             | —     | —            |                |                  |                          |
|               | B118 | WO 96/40792        | 12/19/96 | PCT             | —     | —            |                |                  |                          |
|               | B119 | WO 98/52976        | 11/26/98 | PCT             | —     | —            |                |                  |                          |
| <i>✓</i>      | B120 | WO 00/01822        | 1/13/00  | PCT             | —     | —            |                |                  |                          |

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/7/05*

|                                    |  |   |                 |
|------------------------------------|--|---|-----------------|
| FORM PTO - 1449                    |  | ATTORNEY DOCKET NO.: LEX-011  |                 |
| INFORMATIONAL DISCLOSURE STATEMENT |  | APPLICANT(S): Gillies et al.  |                 |
| JAN 19 2005                        |  | SERIAL NO.: 09/780,668  | CONF. NO.: 8264 |
| TRADEMARK OFFICE                   |  | FILING DATE: February 9, 2001   | GROUP: 1644     |
| OTHER ART, JOURNAL ARTICLES ETC.   |  |   |                 |
| EXAM.<br>INIT.                     | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |   |                 |
| <i>see</i>                         | C268   | Aichele <i>et al.</i> , (1994), "Peptide-Induced T-Cell Tolerance to Prevent Autoimmune Diabetes in a Transgenic Mouse Model," <u>Proc. Natl. Acad. Sci. USA</u> , 91:444-448.  |                 |
|                                    | C269   | Altschul <i>et al.</i> , (1990), "Basic Local Alignment Search Tool," <u>J. Mol. Biol.</u> , 215:403-10.  |                 |
|                                    | C270   | Altschul <i>et al.</i> , (1997), "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs," <u>Nucleic Acids Res.</u> , 25(17):3389-402.   |                 |
|                                    | C271   | Anderson <i>et al.</i> , (1980), "Characterization of the Fc Receptor for IgG on a Human Macrophage Cell Line U937," <u>J. Immunol.</u> , 125:2735-41.  |                 |
|                                    | C272   | Anderson <i>et al.</i> , (1994), "Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2," <u>Clin. Pharmacokinet.</u> , 27(1):19-31.   |                 |
|                                    | C273   | Baici <i>et al.</i> , (1980), "Kinetics of the Different Susceptibilities of the Four Human Immunoglobulin G Subclasses to Proteolysis by Human Lysosomal Elastase," <u>Scand. J. Immunol.</u> , 12(1):41-50.                   |                 |
|                                    | C274   | Barbulescu <i>et al.</i> , (1998), "IL-12 and IL-18 Differentially Regulate the Transcriptional Activity of the Human IFN- $\gamma$ Promoter in Primary CD4+ T Lymphocytes," <u>J. Immunol.</u> , 160:3642-7.                   |                 |
|                                    | C275   | Becker <i>et al.</i> , (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci. USA</u> , 93:7826-7831.                           |                 |
|                                    | C276   | Bednarek <i>et al.</i> , (1991), "Soluble HLA-A2.1 Restricted Peptides that are Recognized by Influenza Virus Specific Cytotoxic T Lymphocytes," <u>J. Immunol. Methods</u> , 139:41-47.  |                 |
|                                    | C277   | Benacerraf <i>et al.</i> , (1959), "The Clearance of Antigen Antibody Complexes from the Blood by the Reticuloendothelial System," <u>J. Immunol.</u> , 82:131-7.   |                 |
|                                    | C278   | Bohm, (1994), "On the Use of LUDI to Search the Fine Chemicals Directory for Ligands of Proteins of Known Three-Dimensional Structure," <u>J. Comput. Aided Mol. Des.</u> , 8:623-32.   |                 |
|                                    | C279   | Bohm, (1994), "The Development of a Simple Empirical Scoring Function to Estimate the Binding Constant for a Protein-Ligand Complex of Known Three-Dimensional Structure," <u>J. Comput. Aided Mol. Des.</u> , 8:243-56.        |                 |
|                                    | C280   | Bohm, (1998), "Prediction of Binding Constants of Protein Ligands: A Fast Method for the Prioritization of Hits Obtained from De Novo Design or 3D Database Search Programs," <u>J. Comput. Aided Mol. Des.</u> , 12(4):309-23. |                 |
|                                    | C281   | Boshart <i>et al.</i> , (1985), "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus," <u>Cell</u> , 41:521-530.   |                 |
|                                    | C282   | Boulianne <i>et al.</i> , (1984), "Production of Functional Chimaeric Mouse/Human Antibody," <u>Nature</u> , 312:643-6.   |                 |

EXAMINER *Daniel S. Saunders*DATE CONSIDERED *7/5/05*

FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

JAN 18 2005



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## OTHER ART, JOURNAL ARTICLES ETC.

| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)   |
|-------------|--|
| <i>Jul</i>  | C283 Bourgois <i>et al.</i> , (1974), "Determination of the Primary Structure of a Mouse IgG2a Immunoglobulin Amino Acid Sequence of the Fc Fragment: Implications for the Evolution of Immunoglobulin Structure and Function," <u>Eur. J. Biochem.</u> , 43:423-35. |
|             | C284 Brambell <i>et al.</i> , (1964), "A Theoretical Model of Gamma-Globulin Catabolism," <u>Nature</u> , 203:1352-54.   |
|             | C285 Brazolot Millan <i>et al.</i> , (1998), "Cpg DNA Can Induce Strong TH1 Humoral and Cell-Mediated Immune Responses against Hepatitis B Surface Antigen in Young Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 95:15553-8.   |
|             | C286 Brekke <i>et al.</i> , (1994), "Human IgG Isotype-Specific Amino Acid Residues Affecting Complement-Mediated Cell Lysis and Phagocytosis," <u>Eur. J. Immunol.</u> , 24:2542-2547.  |
|             | C287 Brem <i>et al.</i> , (1993), "The Combination of Antiangiogenic Agents to Inhibit Primary Tumor Growth and Metastasis," <u>J. Pediatr. Surg.</u> , 28:1253-7.   |
|             | C288 Brocklebank <i>et al.</i> , (2001), "Enumeration of CD34+ Cells in Cord Blood: A Variation on a Single-Platform Flow Cytometric Method Based on the ISHAGE Gating Strategy," <u>Cytometry</u> , 46(4):254-61.   |
|             | C289 Brooks <i>et al.</i> , (1983), "CHARMM: A Program for Macromolecular Energy Minimization and Dynamics Calculations," <u>J. Comput. Chemistry</u> , 4:187-217.   |
|             | C290 Broudy <i>et al.</i> , (1988), "Recombinant Human Erythropoietin: Purification and Analysis of Carbohydrate Linkage," <u>Arch. Biochem. Biophys.</u> , 265:329-36.  |
|             | C291 Bubenik <i>et al.</i> , (1995), "Interleukin-2 Gene Therapy of Residual EL-4 Leukaemia Potentiates the Effect of Cyclophosphamide Pretreatment," <u>J. Cancer Res. Clin. Oncol.</u> , 121:39-43.  |
|             | C292 Bumol <i>et al.</i> , (1982), "Unique Glycoprotein-Proteoglycan Complex Defined by Monoclonal Antibody on Human Melanoma Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 79:1245-9.   |
|             | C293 Camemolla <i>et al.</i> , (1989), "A Tumor-Associated Fibronectin Isoform Generated by Alternative Splicing of Messenger RNA Precursors," <u>J. Cell. Biol.</u> , 108:1139-1148.  |
|             | C294 Camemolla <i>et al.</i> , (1992), "The Inclusion of the Type III Repeat ED-B in the Fibronectin Molecule Generates Conformational Modifications that Unmask a Cryptic Sequence," <u>J. Biol. Chem.</u> , 267(34):24689-24692.                                   |
|             | C295 Cazzola <i>et al.</i> , (1998), "Red Blood Cell Precursor Mass as an Independent Determinant of Serum Erythropoietin Level," <u>Blood</u> , 91:2139-45.   |
|             | C296 Chan <i>et al.</i> , (1992), "Mechanisms of IFN-Gamma Induction by Natural Killer Cell Stimulatory Factor (NKSF/IL-12). Role of Transcription and mRNA Stability in the Synergistic Interaction Between NKSF and IL-2," <u>J. Immunol.</u> , 148:92-98.         |
| <i>✓</i>    | C297 Chappel <i>et al.</i> , (1991), "Identification of the Fc Gamma Receptor Class I Binding Site In Human IgG Through Use of Recombinant IgG1/IgG2 Hybrid and Point-Mutated Antibodies," <u>Proc. Natl. Acad. Sci. USA</u> , 88(20):9036-40.                       |


EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/5/05*



|   |  |  |                 |
|---|--|--|-----------------|
| FORM PTO - 1449   |  | ATTORNEY DOCKET NO.: LEX-011   |                 |
|  |  | APPLICANT(S): Gillies et al.   |                 |
|   |  | SERIAL NO.: 09/780,668   | CONF. NO.: 8264 |
|   |  | FILING DATE: February 9, 2001  | GROUP: 1644     |
| OTHER ART, JOURNAL ARTICLES ETC.  |  |  |                 |
| EXAM.<br>INIT.  | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |  |                 |
| Jes   | C298   | Cheetham, (1998), "NMR Structure of Human Erythropoietin and a Comparison with its Receptor Bound Conformation," <u>Nat. Struct. Biol.</u> , 5:861-6.  |                 |
|   | C299   | Ciardiello <i>et al.</i> , (1996), "Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A," <u>J. Natl. Cancer Inst.</u> , 88:1770-6.   |                 |
|   | C300   | Cirulli <i>et al.</i> , (1998), "KSA Antigen Ep-CAM Mediates Cell-Cell Adhesion of Pancreatic Epithelial Cells: Morphoregulatory Roles in Pancreatic Islet Development," <u>J. Cell Biol.</u> , 140:1519-34.   |                 |
|   | C301   | Cohen <i>et al.</i> , (1998), "An Artificial Cell-Cycle Inhibitor Isolated from a Combinatorial Library," <u>Proc. Natl. Acad. Sci. USA</u> , 95:14272-7.  |                 |
|   | C302   | Congote <i>et al.</i> , (1984), Abstract 364 in "Proceedings 7 <sup>th</sup> Intl. Congress of Endocrinology," Quebec City, Quebec.  |                 |
|   | C303   | Congote, (1983), "Isolation of Two Biologically Active Peptides, Erythrotropin I and Erythrotropin II from Fetal Calf Intestine," <u>Biochem. Biophys. Res. Commun.</u> , 115(2):477-83.   |                 |
|   | C304   | Congote, (1984), "Extraction from Fetal Bovine Serum of Erythrotropin, an Erythroid Cell-Stimulating Factor," <u>Anal. Biochem.</u> , 140:428-33.  |                 |
|   | C305   | Cosenza <i>et al.</i> , (1997), "Disulfide Bond Assignment in Human Interleukin-7 by Matrix-Assisted Laser Desorption/Ionization Mass Spectroscopy and Site-Directed Cysteine to Serine Mutational Analysis," <u>J. Biol. Chem.</u> , 272:32995-3000.          |                 |
|   | C306   | Cunningham <i>et al.</i> , (1989), "High-Resolution Epitope Mapping of Hgh-Receptor Interactions by Alanine-Scanning Mutagenesis," <u>Science</u> , 244:1081-85.   |                 |
|   | C307   | Curiel <i>et al.</i> , (1991), "Adenovirus Enhancement of Transferrin-Polylysine-Mediated Gene Delivery," <u>Proc. Natl. Acad. Sci. USA</u> , 88:8850-4.   |                 |
|   | C308   | Dauber-Osguthorpe <i>et al.</i> , (1988), "Structure and Energetics of Ligand Binding to Proteins: Escherichia Coli Dihydrofolate Reductase-Trimethoprim, A Drug-Receptor System," <u>Proteins</u> , 4(1):31-47.   |                 |
|   | C309   | Daugherty <i>et al.</i> , (1991), "Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins," <u>Nucleic Acid Res.</u> , 19:2471-2476. |                 |
|   | C310   | De Bruijn <i>et al.</i> , (1995), "Phagocyte-Induced Antigen-Specific Activation of Unprimed CD8+ T Cells in Vitro," <u>Eur. J. Immunol.</u> , 25:1274-85.   |                 |
|   | C311   | Delorme <i>et al.</i> , (1992), "Role of Glycosylation on the Secretion and Biological Activity of Erythropoietin," <u>Biochemistry</u> , 31:9871-6.   |                 |
| ✓   | C312   | Desai <i>et al.</i> , (1992), "IL-12 Receptor. II. Distribution and Regulation of Receptor Expression," <u>J. Immunol.</u> , 148:3125-32.  |                 |

|                                   |                               |
|-----------------------------------|-------------------------------|
| EXAMINER <i>David A. Saunders</i> | DATE CONSIDERED <i>7/5/05</i> |
|-----------------------------------|-------------------------------|

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## OTHER ART, JOURNAL ARTICLES ETC.


| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)   |
|-------------|--|
| <i>Dr</i>   | C313 Donnelly <i>et al.</i> , (1993), "Targeted Delivery of Peptide Epitopes to Class I Major Histocompatibility Molecules by a Modified Pseudomonas Exotoxin," <u>Proc. Natl. Acad. Sci. USA</u> , 90:3530-4.                                 |
|             | C314 Donnelly <i>et al.</i> , (1997), "DNA Vaccines," <u>Annu. Rev. Immunol.</u> , 15:617-48.  |
|             | C315 Dube <i>et al.</i> , (1988), "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," <u>J. Biol. Chem.</u> , 263:17516-21.   |
|             | C316 Ellison <i>et al.</i> , (1982), "The Nucleotide Sequence of a Human Immunoglobulin C Gamma 1 Gene," <u>Nucleic Acids Res.</u> , 10:4071-9.  |
|             | C317 Faas <i>et al.</i> , (1993), "Phenotypically Diverse Mouse Thymic Stromal Cell Lines which Induce Proliferation and Differentiation Of Hematopoietic Cells," <u>Eur. J. Immunol.</u> , 23:1201-14.  |
|             | C318 Farmer <i>et al.</i> , (1995), "Distinction Between Gamma C Detection and Function in YT Lymphoid Cells and in the Granulocyte-Macrophage Colony-Stimulating Factor-Responsive Human Myeloid Cell Line, TF-1," <u>Blood</u> , 86:4568-78. |
|             | C319 Fawell <i>et al.</i> , (1994), "Tat-Mediated Delivery of Heterologous Proteins into Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 91:664-8.   |
|             | C320 Fu <i>et al.</i> , (1993), "The Sheep Erythropoietin Gene: Molecular Cloning and Effect of Hemorrhage on Plasma Erythropoietin and Renal/Liver Messenger RNA in Adult Sheep," <u>Mol. Cell. Endocrinol.</u> , 93:107-16.                  |
|             | C321 Gainsford <i>et al.</i> , (1996), "Leptin Can Induce Proliferation, Differentiation, and Functional Activation of Hemopoietic Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 93:14564-14568.   |
|             | C322 Gammon <i>et al.</i> , (1992), "Endogenous Loading of HLA-A2 Molecules with an Analog of the Influenza Virus Matrix Protein-Derived Peptide and Its Inhibition By An Exogenous Peptide Antagonist," <u>J. Immunol.</u> , 148:7-12.        |
|             | C323 Ghetie <i>et al.</i> , (1990), "Disseminated or Localized Growth of a Human B-Cell Tumor (Daudi) in SCID Mice," <u>Intl. J. Cancer</u> , 45:481.  |
|             | C324 Ghetie <i>et al.</i> , (1997), "FcRn: The MHC Class I-Related Receptor that is More Than an IgG Transporter," <u>Immunology Today</u> , 18(12):592-598.   |
|             | C325 Gillies <i>et al.</i> , (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody," <u>Hybridomas</u> , 10(3):347-56.  |
|             | C326 Goldwasser <i>et al.</i> , (1971), "Purification of Erythropoietin," <u>Proc. Natl. Acad. Sci. USA</u> , 68:697-8.  |
|             | C327 Goldwasser <i>et al.</i> , (1975), "Erythropoietin: Assay and Study of its Mode of Action," <u>Methods Enzymol.</u> , 37(Ptb):109-21.   |
| <i>✓</i>    | C328 Halin <i>et al.</i> , (2002), "Enhancement of the Antitumor Activity of Interleukin-12 by Targeted Delivery to Neovasculature," <u>Nature Biotechnology</u> , 20:264-269.   |

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/5/05*




|   |  |  |                 |
|---|--|--|-----------------|
| FORM PTO - 1449   |  | ATTORNEY DOCKET NO.: LEX-011   |                 |
| INFORMATION DISCLOSURE STATEMENT  |  | APPLICANT(S): Gillies et al.   |                 |
|  |  | SERIAL NO.: 09/780,668   | CONF. NO.: 8264 |
|   |  | FILING DATE: February 9, 2001  | GROUP: 1644     |
| OTHER ART, JOURNAL ARTICLES ETC.  |  |  |                 |
| EXAM.<br>INIT.  | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |  |                 |
| <i>Jul</i>  | C329   | Handgretinger <i>et al.</i> , (2001), "Immunological Aspects of Haploidentical Stem Cell Transplantation in Children," <u>Ann. NY Acad. Sci.</u> , 938:340-57.   |                 |
|   | C330   | Hashimoto <i>et al.</i> , (1999), "Differential Antitumor Effects of Administration of Recombinant IL-18 or Recombinant IL-12 are Mediated Primarily by Fas-Fas Ligand- and Perforin-Induced Tumor Apoptosis, Respectively," <u>J. Immunol.</u> , 163:583-9. |                 |
|   | C331   | Henikoff <i>et al.</i> , (1992), "Amino Acid Substitution Matrices from Protein Blocks," <u>Proc. Natl. Acad. Sci. USA</u> , 89:10915-10919.   |                 |
|   | C332   | Hilgers <i>et al.</i> , (1999), "Sulfolipo-Cyclodextrin in Squalane-In-Water as a Novel and Safe Vaccine Adjuvant," <u>Vaccine</u> , 17:219-28.  |                 |
|   | C333   | Holden <i>et al.</i> , (2001), "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents," <u>Proceedings of the American Association for Cancer Research</u> , 42:683, Abstract No. 3675 (XP-002195344).                   |                 |
|   | C334   | Hori <i>et al.</i> , (1987), "Establishment of an Interleukin 2-Dependent Human T Cell Line from a Patient with T Cell Chronic Lymphocytic Leukemia Who is Not Infected with Human T Cell Leukemia/Lymphoma Virus," <u>Blood</u> , 70:1069-72.               |                 |
|   | C335   | Hulet <i>et al.</i> , (1994), "Molecular Basis of Fc Receptor-Function," <u>Adv. Immunol.</u> , 57:1127.   |                 |
|   | C336   | Huston <i>et al.</i> , (1988), "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced In <i>Escherichia Coli</i> ," <u>Proc. Natl. Acad. Sci. USA</u> , 85:5879.                 |                 |
|   | C337   | Isaacs <i>et al.</i> , (1998), "Therapy with Monoclonal Antibodies. II. The Contribution of Fc $\gamma$ Receptor Binding and the Influence of CH1 and CH3 Domains on In Vivo Effector Function," <u>J. Immunol.</u> , 161:3862-3869.                         |                 |
|   | C338   | Jacobs <i>et al.</i> , (1985), "Isolation and Characterization of Genomic And cDNA Clones of Human Erythropoietin," <u>Nature</u> , 313:806-10.  |                 |
|   | C339   | Jefferis <i>et al.</i> , (1990), "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors huFc $\gamma$ R," <u>Mol. Immunol.</u> , 27(12):1237-1240.   |                 |
|   | C340   | Karlin <i>et al.</i> , (1990), "Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes," <u>Proc. Natl. Acad. Sci. USA</u> , 87:2264-8.  |                 |
|   | C341   | Karlin <i>et al.</i> , (1993), "Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences," <u>Proc. Natl. Acad. Sci. USA</u> , 90:5873-7.   |                 |
|   | C342   | Karpusas <i>et al.</i> , (1997), "The Crystal Structure of Human Interferon $\beta$ at 2.2-A Resolution," <u>Proc. Natl. Acad. Sci. USA</u> , 94:11813-11818.  |                 |
|   | C343   | Kelner <i>et al.</i> , (1994), "Lymphotactin: A Cytokine that Represents a New Class of Chemokine," <u>Science</u> , 266:1395-9.   |                 |


EXAMINER

*David A. Saunders*


DATE CONSIDERED

*7/6/05*

|   |  |   |                        |
|---|--|---|------------------------|
| FORM PTO - 1449   |  | ATTORNEY DOCKET NO.: LEX-011  |                        |
| INFORMATION DISCLOSURE STATEMENT  |  | APPLICANT(S): Gillies et al.  |                        |
|  |  | SERIAL NO.: 09/780,668  | CONF. NO.: 8264        |
|   |  | FILING DATE: February 9, 2001   | GROUP: 1644            |
| OTHER ART, JOURNAL ARTICLES ETC.  |  |   |                        |
| EXAM.<br>INIT.  | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |   |                        |
|  | C344   | Kirkman <i>et al.</i> , (1989), "Prolongation of Cardiac Allograft Survival in Murine Recipients Treated with a Diphtheria Toxin-Related Interleukin-2 Fusion Protein," <u>Transplantation</u> , 47(2):327-330.   |                        |
|   | C345   | Klinman <i>et al.</i> , (1997), "Contribution of CPG Motifs to the Immunogenicity of DNA Vaccines," <u>J. Immunol.</u> , 158:3635-9.  |                        |
|   | C346   | Kuntz <i>et al.</i> , (1982), "A Geometric Approach to Macromolecule-Ligand Interactions," <u>J. Mol. Biol.</u> , 161:269-88.   |                        |
|   | C347   | Kurtz, (1982), "A New Candidate for the Regulation of Erythropoiesis. Insulin-Like Growth Factor I," <u>FEBS Lett.</u> , 149(1):105-8.  |                        |
|   | C348   | Lai <i>et al.</i> , (1986), "Structural Characterization of Human Erythropoietin," <u>J. Biol. Chem.</u> , 261:3116-21.   |                        |
|   | C349   | Lai <i>et al.</i> , (1998), "DNA Vaccines," <u>Crit. Rev. Immunol.</u> , 18:449-84.   |                        |
|   | C350   | Lanza <i>et al.</i> , (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenized with Residues 41-55 of the First Extracellular Domain," <u>Proc. Natl. Acad. Sci. USA</u> , 90:11683-7.  |                        |
|   | C351   | Lawn <i>et al.</i> , (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," <u>Proc. Natl. Acad. Sci. USA</u> , 78:5435-9.  |                        |
|   | C352   | Lin <i>et al.</i> , (1985), "Cloning and Expression of the Human Erythropoietin Gene," <u>Proc. Natl. Acad. Sci. USA</u> , 82:7580-4.   |                        |
|   | C353   | Lin <i>et al.</i> , (1986), "Monkey Erythropoietin Gene: Cloning, Expression and Comparison with the Human Erythropoietin Gene," <u>Gene</u> , 44:201-9.  |                        |
|   | C354   | Lode <i>et al.</i> , (1998), "Gene Therapy with a Single Chain Interleukin 12 Fusion Protein Induces T Cell-Dependent Protective Immunity in a Syngeneic Model of Murine Neuroblastoma," <u>Proc. Natl. Acad. Sci. USA</u> , 95:2475-80.  |                        |
|   | C355   | Lorenz <i>et al.</i> , (1999), "Induction of Anti-Tumor Immunity Elicited by Tumor Cells Expressing a Murine LFA-3 Analog Via a Recombinant Vaccinia Virus," <u>Hum. Gene Ther.</u> , 10:623-31.  |                        |
|   | C356   | Lotze <i>et al.</i> , (1996), "Cytokine Gene Therapy of Cancer Using Interleukin-12: Murine and Clinical Trials," <u>Ann. NY Acad. Sci.</u> , 795:440-54.   |                        |
|   | C357   | Macdougall <i>et al.</i> , (1999), "Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients," <u>J. Am. Soc. Nephrol.</u> , 10:2392-5.   |                        |
|   | C358   | MacLean <i>et al.</i> , (1996), "Enhancing the Effect of Theratope STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide," <u>J. Immunother.</u> , 19(4):309-316.   |                        |
| ✓   | C359   | Maghazachi <i>et al.</i> , (1997), "Interferon-Inducible Protein-10 and Lymphotoxin Induce the Chemotaxis and Mobilization of Intracellular Calcium in Natural Killer Cells through Pertussis Toxin-Sensitive and -Insensitive Heterotrimeric G-Proteins," <u>FASEB J.</u> , 11:765-74. |                        |
| EXAMINER  |     |   | DATE CONSIDERED 7/5/05 |


|   |  |   |                 |
|---|--|---|-----------------|
| FORM PTO - 1449   |  | ATTORNEY DOCKET NO.: LEX-011  |                 |
| INFORMATION DISCLOSURE STATEMENT  |  | APPLICANT(S): Gillies et al.  |                 |
|  |  | SERIAL NO.: 09/780,668  | CONF. NO.: 8264 |
|   |  | FILING DATE: February 9, 2001   | GROUP: 1644     |
| OTHER ART, JOURNAL ARTICLES ETC.  |  |   |                 |
| EXAM. INIT.   | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |   |                 |
| <i>ms</i>   | C360   | Maloy <i>et al.</i> , (2001), "Regulatory T Cells in the Control of Immune Pathology," <u>Nature Immunol.</u> , 2:816-22.   |                 |
|   | C361   | Mariani <i>et al.</i> , (1997), "Tumor Targeting Potential of the Monoclonal Antibody BC-1 against Oncofetal Fibronectin in Nude Mice Bearing Human Tumor Implants," <u>Cancer</u> , 80:2378-84.            |                 |
|   | C362   | Marshall <i>et al.</i> , (1995), "Prediction of Peptide Affinity to HLA-DR Molecules," <u>Biomed. Pept. Proteins Nucleic Acids</u> , 1(3):157-62.   |                 |
|   | C363   | Marshall, K.W., (1994), "Role of the Polymorphic Residues in HLA-DR Molecules in Allele-Specific Binding of Peptide Ligands," <u>J. Immunol.</u> , 152:4946-57.   |                 |
|   | C364   | Martin <i>et al.</i> , (2001), "Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex: Mechanism of pH-Dependent Binding," <u>Mol. Cell.</u> , 7(4):867-77.  |                 |
|   | C365   | McDonald, (1986), "Cloning, Sequencing, and Evolutionary Analysis of the Mouse Erythropoietin Gene," <u>Mol. Cell. Biol.</u> , 6:842-8.   |                 |
|   | C366   | McGonigle <i>et al.</i> , (1984), "Erythropoietin Deficiency and Inhibition of Erythropoiesis in Renal Insufficiency," <u>Kidney Int.</u> , 25(2):437-44.   |                 |
|   | C367   | McMahan <i>et al.</i> , (1991), "A Novel IL-1 Receptor, Cloned From B-Cells by Mammalian Expression is Expressed in Many Cell Types," <u>EMBO J.</u> , 10:2821-32.  |                 |
|   | C368   | McMahon <i>et al.</i> , (1990), "Pharmacokinetics and Effects of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Injections in Healthy Volunteers," <u>Blood</u> , 76:1718-22           |                 |
|   | C369   | Mehrotra <i>et al.</i> , (1993), "Effects of IL-12 on the Generation of Cytotoxic Activity in Human CD8+ T Lymphocytes," <u>J. Immunol.</u> , 151:2444-52.  |                 |
|   | C370   | Menard <i>et al.</i> , (1983), "Generation of Monoclonal Antibodies Reacting with Normal and Cancer Cells of Human Breast," <u>Cancer Res.</u> , 43:1295-300.   |                 |
|   | C371   | Miyake <i>et al.</i> , (1977), "Purification of Human Erythropoietin," <u>J. Biol. Chem.</u> , 252:5558-64.   |                 |
|   | C372   | Morrison <i>et al.</i> , (1984), "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains," <u>Proc. Natl. Acad. Sci. USA</u> , 81:6851-5.                      |                 |
|   | C373   | Nagao <i>et al.</i> , (1992), "Nucleotide Sequence of Rat Erythropoietin," <u>Biochim. Biophys. Acta</u> , 1171(1):99-102.  |                 |
|   | C374   | Nastala <i>et al.</i> , (1994), "Recombinant IL-12 Administration Induces Tumor Regression in Association with IFN-Gamma Production," <u>J. Immunol.</u> , 153:1697-706.                                    |                 |
|   | C375   | Naughton <i>et al.</i> , (1983), "Evidence for an Erythropoietin-Stimulating Factor in Patients with Renal and Hepatic Disease," <u>Acta Haematol.</u> , 69:171-9.  |                 |
|   | C376   | Noguchi <i>et al.</i> , (1994), "A Mouse Mutant P53 Product Recognized by CD4+ and CD8+ T Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 91:3171-5. <i>Nez et al., (2004), Clin. Cancer Res., 10, 4839-47.</i> |                 |

|                                   |                               |
|-----------------------------------|-------------------------------|
| EXAMINER <i>David A. Saunders</i> | DATE CONSIDERED <i>7/5/05</i> |
|-----------------------------------|-------------------------------|

|   |  |   |                 |
|---|--|---|-----------------|
| FORM PTO - 1449   |  | ATTORNEY DOCKET NO.: LEX-011  |                 |
| INFORMATION DISCLOSURE STATEMENT  |  | APPLICANT(S): Gillies et al.  |                 |
|  |  | SERIAL NO.: 09/780,668  | CONF. NO.: 8264 |
|   |  | FILING DATE: February 9, 2001   | GROUP: 1644     |
| OTHER ART, JOURNAL ARTICLES ETC.  |  |   |                 |
| EXAM. INIT.   | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |   |                 |
| gal   | C377   | Orlandi <i>et al.</i> , (1989), "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction," <u>Proc. Natl. Acad. Sci. USA</u> , 86:3833-7.   |                 |
| 1   | C378   | Palmer <i>et al.</i> , (2001), "Phase I Study of the BLP 25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non-Small-Cell Lung Cancer," <u>Clinical Lung Cancer</u> , 3(1):49-57.                        |                 |
|   | C379   | Palucka <i>et al.</i> , (1998), "Dendritic Cells as the Terminal Stage of Monocyte Differentiation," <u>J. Immunol.</u> , 160:4587-95.  |                 |
|   | C380   | Panina-Bordignon <i>et al.</i> , (1989), "Universally Immunogenic T Cell Epitopes: Promiscuous Binding to Human MHC Class II and Promiscuous Recognition by T Cells," <u>Eur. J. Immunol.</u> , 19:2237-42                                    |                 |
|   | C381   | Pavlovic-Kentera <i>et al.</i> , (1980), "Effects of Prostaglandin Synthetase Inhibitors, Salt Overload and Renomedullary Dissection on the Hypoxia Stimulated Erythropoietin Production in Rats," <u>Expt. Hematol.</u> , 8(Supp. 8):283-92. |                 |
|   | C382   | Pedley <i>et al.</i> (1999), "Enhancement of Antibody-Directed Enzyme Prodrug Therapy in Colorectal Xenografts by an Antivascular Agent," <u>Cancer Res.</u> , 59:3998-4003.  |                 |
|   | C383   | Perussia <i>et al.</i> , (1992), "Natural Killer (NK) Cell Stimulatory Factor or IL-12 Has Differential Effects on the Proliferation of TCR-Alpha Beta+, TCR-Gamma Delta+ T Lymphocytes, and NK Cells," <u>J. Immunol.</u> , 149:3495-502.    |                 |
|   | C384   | Pluschke <i>et al.</i> , (1996), "Molecular Cloning of a Human Melanoma-Associated Chondroitin Sulfate Proteoglycan," <u>Proc. Natl. Acad. Sci. USA</u> , 93:9710-5.  |                 |
|   | C385   | Poon <i>et al.</i> , (1995), "Structure and Function of Several Anti-Dansyl Chimeric Antibodies Formed by Domain Interchanges Between Human IgM and Mouse IgG2b," <u>J. Biol. Chem.</u> , 270:8571-7.   |                 |
|   | C386   | Queen <i>et al.</i> , (1989), "A Humanized Antibody that Binds to the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 86:10029-33.   |                 |
|   | C387   | Radhakrishnan <i>et al.</i> , (1996), "Zinc Mediated Dimer of Human Interferon-Alpha 2b Revealed by X-Ray Crystallography," <u>Structure</u> 4:1453-63.   |                 |
|   | C388   | Ramachandran <i>et al.</i> , (1968) "Conformation of Polypeptides and Proteins," <u>Adv. Prot. Chem.</u> , 23:283-438. (1968) (At Pgs. 285-94).   |                 |
|   | C389   | Rarey <i>et al.</i> , (1995), "Time-Efficient Docking of Flexible Ligands into Active Sites Of Proteins," <u>Proc. Int. Conf. Intell. Syst. Mol. Biol.</u> 3:300-8.   |                 |
|   | C390   | Resegotti <i>et al.</i> , (1981), "Treatment of Aplastic Anaemia with Methenolone, Stanozolol and Nandrolone. A Report of 130 Cases," <u>Panminerva Med.</u> , 23:243-8.  |                 |
|   | C391   | Riechmann <i>et al.</i> , (1988), "Reshaping Human Antibodies for Therapy," <u>Nature</u> , 332:323-7.  |                 |
| ✓   | C392   | Robinson <i>et al.</i> , (1998), "Optimizing the Stability of Single-Chain Proteins by Linker Length and Composition Mutagenesis," <u>Proc. Natl. Acad. Sci. USA</u> , 95:5929-34.  |                 |
| EXAMINER David A. Spencer   |  | DATE CONSIDERED 7/5/05  |                 |

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## OTHER ART, JOURNAL ARTICLES ETC.

| EXAM.<br>INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)   |
|----------------|--|
| <i>g</i>       | C393 Rothmann et al., (1982), "Erythropoietin-Dependent Erythrocytosis associated with Hepatic Angiosarcoma," <u>J. Surg. Oncol.</u> , 20:105-8.   |
| <i>1</i>       | C394 Runkel et al., (1998), "Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon-B (IFN-B)," <u>Pharmaceutical Res.</u> , 15:641-649.  |
|                | C395 Sakano et al., (1980), "Two Types of Somatic Recombination are Necessary for the Generation of Complete Immunoglobulin Heavy-Chain Genes," <u>Nature</u> , 286:676-683.   |
|                | C396 Sali et al., (1993), "Comparative Protein Modelling by Satisfaction of Spatial Restraints," <u>J. Mol. Biol.</u> , 234:779-815.   |
|                | C397 Schechter et al., (1997), "Tissue Factor is Induced by Monocyte Chemoattractant Protein-1 in Human Aortic Smooth Muscle And THP-1 Cells," <u>J. Biol. Chem.</u> , 272:28568-73.   |
|                | C398 Senior et al., (2000), "Cleavage of a Recombinant Human Immunoglobulin A2 (IgA2)-IgA1 Hybrid Antibody by Certain Bacterial IgA1 Proteases," <u>Infect. Immun.</u> , 68(2):463-9.  |
|                | C399 Sharp et al., (1988), "Codon Usage Patterns in <i>Escherichia coli</i> , <i>Bacillus subtilis</i> , <i>Saccharomyces cerevisiae</i> , <i>Schizosaccharomyces pombe</i> , <i>Drosophila melanogaster</i> and <i>Homo sapiens</i> ; a Review of the Considerable Within-Species Diversity," <u>Nucleic Acids Res.</u> , 16(17):8207-8211. |
|                | C400 Simonsen et al., (1983), "Isolation and Expression of an Altered Mouse Dihydrofolate Reductase cDNA," <u>Proc. Natl. Acad. Sci. USA</u> , 80:2495-2499.   |
|                | C401 Smith et al., (1981), "Identification of Common Molecular Subsequences," <u>J. Mol. Biol.</u> , 147:195-197.  |
|                | C402 Soligo et al., (1998), "Expansion of Dendritic Cells Derived from Human CD34+ Cells in Static And Continuous Perfusion Cultures," <u>Br. J. Haematol.</u> , 101:352-63.   |
|                | C403 Spivak et al., (1989), "The In Vivo Metabolism of Recombinant Human Erythropoietin in The Rat," <u>Blood</u> , 73:90-9.   |
|                | C404 Sturniolo et al., (1999), "Generation of Tissue-Specific and Promiscuous HLA Ligand Databases Using DNA Microarrays and Virtual HLA Class II Matrices," <u>Nat. Biotech.</u> , 17(6):555-61.  |
|                | C405 Suliman et al., (1996), "Cloning of a cDNA Encoding Bovine Erythropoietin and Analysis of Its Transcription in Selected Tissues," <u>Gene</u> , 171:275-80.   |
|                | C406 Takahashi et al. (2000), "Immunologic Self-Tolerance Maintained by CD25+ CD4+ Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte-Associated Antigen," <u>J. Exp. Med.</u> , 192(2):303-309.  |
|                | C407 Takai, (2002), "Roles of Fc Receptors in Autoimmunity," <u>Nat. Rev. Immunol.</u> , 2(8):580-92.  |
|                | C408 Taniguchi et al., (1980), "Expression of the Human Fibroblast Interferon Gene in <i>Escherichia Coli</i> ," <u>Proc. Natl. Acad. Sci. USA</u> , 77:5230-5233.   |

EXAMINER


*David A. Saunders*

DATE CONSIDERED

*7/5/05*

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## OTHER ART, JOURNAL ARTICLES ETC.

EXAM.  
INIT.

OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

|   |      |  |
|---|------|--|
| ✓ | C409 | Thurner, (1999), "Generation of Large Numbers of Fully Mature and Stable Dendritic Cells from Leukapheresis Products for Clinical Application," <u>J. Immunol. Methods</u> , 223:1-15.   |
|   | C410 | Tiruppathi <i>et al.</i> , (1996), "Isolation and Characterization of a Cell Surface Albumin-Binding Protein from Vascular Endothelial Cells," <u>Proc. Nat. Acad. Sci. USA</u> , 93:250-4.  |
|   | C411 | Van Den Eynde <i>et al.</i> , (1989), "Presence on a Human Melanoma of Multiple Antigens Recognized By Autologous CTL," <u>Int. J. Cancer</u> , 44:634-40.   |
|   | C412 | Van Der Bruggen <i>et al.</i> , (1991), "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma," <u>Science</u> , 254:1643-7.   |
|   | C413 | Van Heyningen <i>et al.</i> , (1982), "Human MHC Class II Molecules as Differentiation Markers," <u>Immunogenetics</u> , 16:459-69.  |
|   | C414 | Voest <i>et al.</i> , (1995), "Inhibition of Angiogenesis in Vivo by Interleukin 12," <u>J. Natl. Canc. Inst.</u> , 87:581-6.  |
|   | C415 | Von Heijne <i>et al.</i> , (1986), "A New Method for Predicting Signal Sequence Cleavage Sites," <u>Nucleic Acid Res.</u> , 14:4683-4690.  |
|   | C416 | Ward <i>et al.</i> , (1995), "The Effector Functions of Immunoglobulins: Implications for Therapy," <u>Therapeutic Immunology</u> , 2:77-94.   |
|   | C417 | Watson <i>et al.</i> , (1984), "Compilation of Published Signal Sequences," <u>Nucleic Acid Res.</u> , 12:5145-5164.   |
|   | C418 | Weitkamp <i>et al.</i> , (1973), "Additional Data on the Population Distribution of Human Serum Albumin Genes; Three New Variants," <u>Ann. Hum. Genet.</u> , 37:219-26.   |
|   | C419 | Wetzel <i>et al.</i> , (2001), "BAY50-4798, an Interleukin-2 (IL <sub>2</sub> ) Variant, demonstrates Selective Activation of Human and Chimpanzee T Cells Relative to NK Cells but Shows Less Selectivity for T Cells from Monkeys and Rodents," <u>ASCO Annual Meeting</u> , Abstract 1051.. |
|   | C420 | Woof <i>et al.</i> , (1986), "Localisation of the Monocyte-Binding Region on Human Immunoglobulin G," <u>Mol. Immunol.</u> , 23:319-30.  |
|   | C421 | Wu <i>et al.</i> , (1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin," <u>Biochemical and Biophysical Research Communications</u> , 236:651-654.  |
|   | C422 | Wyatt <i>et al.</i> , (1998), "The Antigenic Structure of the HIV Gp120 Envelope Glycoprotein," <u>Nature</u> , 393:705-11.  |
|   | C423 | Wysocka <i>et al.</i> , (1995), "Interleukin-12 is Required for Interferon-Gamma Production and Lethality in Lipopolysaccharide-Induced Shock in Mice," <u>Eur. J. Immunol.</u> , 25:672-6.  |
|   | C424 | Yan <i>et al.</i> , (1996), "Characterization of an Ig VH Idiotope that Results in Specific Homophilic Binding and Increased Avidity for Antigen," <u>J. Immunol.</u> , 157:1582-8.  |
| ✓ | C425 | Yeh <i>et al.</i> , (1992), "Design of Yeast-Secreted Albumin Derivatives for Human Therapy: Biological and Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate," <u>Proc. Natl. Acad. Sci. USA</u> , 89:1904-8.   |







EXAMINER

David A. Summers

DATE CONSIDERED

7/06/05



|   |  |   |   |
|---|--|---|---|
| FORM PTO - 1449   |  | ATTORNEY DOCKET NO.: LEX-011  |   |
| INFORMATION DISCLOSURE STATEMENT  |  | APPLICANT(S): Gillies et al.  |   |
|  |  | SERIAL NO.: 09/780,668  | CONF. NO.: 8264   |
|   |  | FILING DATE: February 9, 2001   | GROUP: 1644   |
| OTHER ART, JOURNAL ARTICLES ETC.  |  |   |   |
| EXAM.<br>INIT.  | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |   |   |
|  | C426   | Zhang <i>et al.</i> , (1994), "Structure/Activity Analysis of Human Monocyte Chemoattractant Protein-1 (MCP-1) by Mutagenesis. Identification of a Mutated Protein that Inhibits MCP-1-Mediated Monocyte Chemotaxis," <u>J. Biol. Chem.</u> , 269:15918-24. |   |
|  | C427   | Zhu <i>et al.</i> , (2001), "MHC Class I-Related Neonatal Fc Receptor for IgG is Functionally Expressed in Monocytes, Intestinal Macrophages and Dendritic Cells," <u>J. Immunol.</u> , 166:3266-3276.  |   |
|  | C428   | Zuckier <i>et al.</i> , (1998), "Chimeric Human-Mouse IgG Antibodies with Shuffled Constant Region Exons Demonstrate that Multiple Domains Contribute to In Vivo Half-Life," <u>Cancer Res.</u> , 58(17):3905-8.  |   |
| EXAMINER  |       |   | DATE CONSIDERED  |

3166771

|          |                 |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|